Document:

EX10.4

 Exhibit 10.4 

MANUFACTURING SERVICES AGREEMENT 

BY AND BETWEEN 
 EMERGENT
BIOSOLUTIONS INC. 
 AND 

APTEVO THERAPEUTICS INC. 
 DATED
AS OF [●], 2016 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE I DEFINITIONS
	  	 	1	  
		
	 ARTICLE II GENERAL TERMS
	  	 	10	  
			
	 2.1
	 	 Project Management.
	  	 	10	  
	 2.2
	 	 Exclusivity
	  	 	12	  
	 2.3
	 	 Manufacturing and Product Quality.
	  	 	12	  
	 2.4
	 	 Master Batch Records
	  	 	12	  
	 2.5
	 	 Improvements.
	  	 	13	  
	 2.6
	 	 Licenses
	  	 	14	  
	 2.7
	 	 Arising Intellectual Property; Improvements.
	  	 	15	  
	 2.8
	 	 Delegation.
	  	 	16	  
	 2.9
	 	 Invoices.
	  	 	16	  
		
	 ARTICLE III MANUFACTURING SERVICES
	  	 	16	  
			
	 3.1
	 	 Purchases.
	  	 	16	  
	 3.2
	 	 Manufacturing.
	  	 	18	  
	 3.3
	 	 Storage, Use and Segregation of Work-in-Process and Product.
	  	 	19	  
	 3.4
	 	 Release Documents
	  	 	19	  
	 3.5
	 	 [Reserved]
	  	 	19	  
	 3.6
	 	 Product Inspection; Acceptance.
	  	 	19	  
	 3.7
	 	 Emergent Liability for Non-Conforming Batches
	  	 	20	  
	 3.8
	 	 Cooperation in Investigations; Disposition of Non-Conforming Product.
	  	 	20	  
	 3.9
	 	 Withdrawals and Recalls.
	  	 	20	  
	 3.10
	 	 Title and Risk of Loss.
	  	 	21	  
	 3.11
	 	 Packaging
	  	 	21	  
	 3.12
	 	 Labeling.
	  	 	21	  
	 3.13
	 	 New Jurisdictions.
	  	 	21	  
	 3.14
	 	 Price and Payment Terms.
	  	 	22	  
	 3.15
	 	 Automatic Pricing Adjustments.
	  	 	22	  
	 3.16
	 	 Other Pricing Adjustments.
	  	 	22	  
	 3.17
	 	 General Payment Terms.
	  	 	23	  
	 3.18
	 	 Payment without Deductions.
	  	 	23	  
	 3.19
	 	 Stability Testing
	  	 	23	  
	 3.20
	 	 Regulatory Audits
	  	 	23	  
	 3.21
	 	 Disposal or Maintenance of Products and Data.
	  	 	24	  
	 3.22
	 	 Second Source.
	  	 	24	  
	 3.23
	 	 Delivery Failures.
	  	 	24	  

  
 i 

							
	 ARTICLE IV PACKAGING SERVICES FOR IXINITY
	  	 	25	  
		
	 ARTICLE V LOGISTICS SERVICES
	  	 	25	  
			
	 5.1
	 	 Scope
	  	 	25	  
	 5.2
	 	 Shipment of Products.
	  	 	25	  
	 5.3
	 	 Export Documentation
	  	 	25	  
	 5.4
	 	 Price and Payment Terms.
	  	 	26	  
	 5.5
	 	 Delivery Loss.
	  	 	26	  
		
	 ARTICLE VI CONFIDENTIALITY
	  	 	26	  
			
	 6.1
	 	 Confidentiality Obligations under the SDA.
	  	 	26	  
		
	 ARTICLE VII REPRESENTATIONS, WARRANTIES & COVENANTS
	  	 	26	  
			
	 7.1
	 	 Warranties by both Parties.
	  	 	26	  
	 7.2
	 	 Additional Warranties by Emergent
	  	 	27	  
	 7.3
	 	 Additional Warranties by Aptevo.
	  	 	28	  
	 7.4
	 	 Disclaimer of Warranties
	  	 	28	  
		
	 ARTICLE VIII INDEMNIFICATION AND LIMITATION ON LIABILITY
	  	 	29	  
			
	 8.1
	 	 Indemnification by Emergent.
	  	 	29	  
	 8.2
	 	 Indemnification by Aptevo.
	  	 	29	  
	 8.3
	 	 Conditions.
	  	 	29	  
	 8.4
	 	 Limitation on Liability.
	  	 	30	  
	 8.5
	 	 Interaction with the SDA and other Ancillary Agreements.
	  	 	31	  
		
	 ARTICLE IX TERM AND TERMINATION
	  	 	31	  
			
	 9.1
	 	 Term
	  	 	31	  
	 9.2
	 	 Termination.
	  	 	31	  
	 9.3
	 	 Outstanding Obligations.
	  	 	32	  
	 9.4
	 	 Manufacturing Failure; CMO Appointment
	  	 	32	  
		
	 ARTICLE X INSURANCE
	  	 	33	  
			
	 10.1
	 	 Product Liability Insurance.
	  	 	33	  
	 10.2
	 	 Insurance; Liability to Third Persons:
	  	 	33	  
		
	 ARTICLE XI DISPUTE RESOLUTION
	  	 	34	  
			
	 11.1
	 	 Resolution Process.
	  	 	34	  
	 11.2
	 	 Arbitration.
	  	 	34	  
	 11.3
	 	 Expert Resolution for Lack of Agreement in Section 3.16.3.
	  	 	35	  
	 11.4
	 	 Interim Relief.
	  	 	36	  
	 11.5
	 	 Expenses.
	  	 	36	  

  
 ii 

							
	 ARTICLE XII MISCELLANEOUS
	  	 	36	  
			
	 12.1
	 	 Provisions from the SDA.
	  	 	36	  
	 12.2
	 	 Notices
	  	 	36	  
	 12.3
	 	 Force Majeure
	  	 	37	  
	 12.4
	 	 Assignability
	  	 	37	  
	 12.5
	 	 Independent Contractors
	  	 	39	  
	 12.6
	 	 Bankruptcy.
	  	 	39	  
	 12.7
	 	 Survival.
	  	 	39	  
	 12.8
	 	 Further Assurances.
	  	 	39	  
	 12.9
	 	 Quality Agreement.
	  	 	39	  

  
 iii 

 MANUFACTURING SERVICES AGREEMENT 

This MANUFACTURING SERVICES AGREEMENT, dated as of [●], 2016 (this “Agreement”), is made and entered into by and
between Emergent BioSolutions Inc., a Delaware corporation (“Emergent”), and Aptevo Therapeutics Inc., a Delaware corporation (“Aptevo”). Aptevo and Emergent are referred to together as the
“Parties” and individually as a “Party.” Unless otherwise defined in this Agreement, all capitalized terms used in this Agreement shall have the meaning set forth in the Separation and Distribution Agreement
(“SDA”) or, if not therein, in the Transition Services Agreement (“TSA”), or, if not therein, in the Canadian Distributor Agreement (“CDA”), or, if not therein, in the Product Licensing Agreement
(the “PLA”), or, if not therein, in the Trademark License Agreement (“TLA”), each dated as of the date hereof, by and between Emergent and Aptevo. The Parties acknowledge and agree that this Agreement is an
Ancillary Agreement under the SDA. 
 WHEREAS, Aptevo and Emergent have entered into the SDA, the TSA, the CDA, the TLA and the PLA; 

WHEREAS, Aptevo is a therapeutics company pursuing the research, development, and commercialization of pharmaceutical products; and 

WHEREAS, Emergent has the capacity to meet Aptevo’s applicable manufacturing, distribution and other needs with respect to the Products;

 NOW, THEREFORE, in consideration of the mutual promises of the Parties, and of good and valuable consideration, it is agreed by and
between the Parties as follows: 
 ARTICLE I 

DEFINITIONS 
 For the purpose of
this Agreement, the following terms shall have the following meanings. 
 “3PL-Only Products” means the pharmaceutical
products set forth in Item 1 of Schedule E. 
 “3PL Services” has the meaning set forth in ARTICLE V.

 “Acceptance Criteria” means, with respect to a Product, the tests and other factors set forth in the applicable Master
Batch Record that, once satisfied, require Aptevo to accept such Product as conforming to the Specifications and other requirements set forth herein. 

“Acquiring Entity” means a Person that (a) (i) acquires control (as defined in the definition of Affiliate under
the SDA), after the Effective Time, of Aptevo or an Aptevo Affiliate or any member of the Aptevo Group to which rights or interests under this Agreement or the PLA or with respect to any of the Products have been assigned or licensed or (ii) is
assigned any right or interest under this Agreement or the PLA and (b) was a Third Party until the time of such acquisition or assignment. 

  
 1 

 “Agreement” means this agreement, including any schedules. 

“Applicable Laws” means (a) for Emergent, the Laws of the jurisdictions where the Manufacturing Facility or Storage
Facilities are located, as applicable, and such other Laws as may govern Emergent’s performance of its Manufacturing services and 3PL Services under this Agreement (but in no event shall any Laws that may govern the distribution, marketing,
import or export of the Products be construed as Applicable Laws with respect to Emergent under this Agreement); and (b) for Aptevo and the Products, the Laws of the United States, Canada, and any other jurisdictions where the Products are
manufactured, distributed, stored or marketed. 
 “Aptevo Certificate of Analysis” means, with respect to a Batch of a
Product, the document for such Batch of such Product prepared by Aptevo, reporting the results of testing of such Batch of Product. 

“Aptevo IP” has the meaning set forth in Section 2.6.1. 

“Aptevo Representative” has the meaning set forth in Section 2.1.2. 

“Background Emergent IP” means any and all Intellectual Property rights owned or controlled by Emergent or any of its
Affiliates as of immediately after the Effective Time or thereafter during the term of this Agreement, including its rights in its own Confidential Information, trade secrets, and the like. 

“Bankruptcy Code” has the meaning set forth in Section 12.6. 

“Batch” means, with respect to a Product, a uniform quantity of drug substance consisting of the Minimum Vials resulting from
a single run of such Product produced by a single execution of the instructions specified in the applicable Batch Record within the meaning of 21 CFR part 210.3(b)(2) or within the meaning of 21 CFR part 600.3(x), or its successor as in effect from
time to time. 
 “Batch Record” means, with respect to a Product, the batch production and control record containing the
set of detailed processing instructions which are to be followed by Emergent to produce one Batch of the relevant Product as defined in 21 CFR part 211.188, or its successor as in effect from time to time. 

“Binding Purchase Order” means any Purchase Order that is accepted by Emergent pursuant to Section 3.1.2. 

“Binding Six Month Forecast” has the meaning set forth in Section 3.1.1. 

“CFR” means the United States Code of Federal Regulations. 

  
 2 

 “Competing Program” means (a) the research, development, making, having
made, manufacturing, using, selling, offering for sale, importing or otherwise exploiting of any product substantially similar to any of the Products, or any activity involving any process or technology that is materially related to the
Manufacturing Technology, including: so-called hyperimmune products; products, either marketed or being developed as therapeutics, comprising polyclonal sera collected from persons or animals that possess antibodies with specificity against a given
antigen; and products derived from blood, plasma and blood components, such as clotting factors and (b) the making, having made or manufacturing of any Product. For clarity, Competing Program excludes (i) the research, development, making,
having made, manufacturing, using, selling, offering for sale, importing or otherwise exploiting of any recombinant protein product that is not a hyperimmune product and (ii) the research, development, using, selling, offering for sale,
importing or otherwise exploiting (but not making, having made or manufacturing) any Product. 
 “Conforming Product” means
Product that, upon the issuance of the Emergent Release Documents with respect to such Product, meets the Specifications and was Manufactured in conformance with the terms of the Quality Agreement. 

“CPR” has the meaning set forth in Section 11.1.2. 

“Credit” means that Emergent shall, as applicable, (a) not invoice Aptevo for the applicable Manufacturing Fee,
(b) cancel the already-issued invoice for the applicable Manufacturing Fee, or (c) credit the amount of the applicable Manufacturing Fee against any other amounts owed by Aptevo to Emergent under this Agreement. For the avoidance of doubt,
any Products for which Aptevo receives a Credit shall count towards the Minimum Annual Order. 
 “Current Good Manufacturing
Practices” or “GMP” or “cGMP” means the regulatory requirements for the then-current good manufacturing practice as provided for (and as amended from time to time) in the Current Good Manufacturing Practice
Regulations of the U.S. Code of Federal Regulations Title 21 (21 CFR §§ 210 and 211), in Part C, Division 2 of the Food and Drug Regulations (Canada) and in Commission Directive 2003/94/EC, as amended from time to time and the principles
and practices set down in the current edition of the Rules Governing Medicinal Products in the European Union, Volume IV, Good Manufacturing Practice for Medicinal Products. 

“Debarred Entity” has the meaning set forth in Section 7.2.4. 

“Debarred Individual” has the meaning set forth in Section 7.2.3. 

“Delivery” means, with respect to a Vial of Product, the earlier of (i) the Release of such Vial of such Product or
(ii) fifteen (15) days after the issuance of the Emergent Release Documents with respect to such Vial of such Product. “Deliver” shall have the corresponding meaning. 

  
 3 

 “Dispute” has the meaning set forth in Section 11.1.1. 

“Dispute Notice” has the meaning set forth in Section 11.1.2. 

“Distribution Destination” means, with respect to each Vial within a Purchase Order, the area within the Territory that is
the final destination for such Vial. The Distribution Destination may be one of the following three designations: (i) the United States, (ii) Canada or (iii) the rest of the world (“ROW”). 

“Distributor” has the meaning set forth in Section 7.2.7. 

“Emergent Certificate of Analysis” means, with respect to a Batch of a Product, the document for such Batch of such Product
prepared by Emergent, reporting the results of testing of such Batch of Product and indicating that the Batch has met the Specifications. 

“Emergent Certificate of Compliance” means, with respect to a Batch of Product, a certificate from Emergent confirming that
such Batch of such Product was Manufactured under Current Good Manufacturing Practices. 
 “Emergent-Owned IP” has the
meaning set forth in Section 2.7.2. 
 “Emergent Release Documents” means, with respect to a Batch of Product,
the following documents: (a) Emergent’s Batch Record for such Batch of such Product, (b) the Emergent Certificate of Compliance for such Batch of such Product, (c) the applicable Emergent Certificate of Analysis and (d) such
other documents required by the Quality Agreement for Emergent’s release of Product. 
 “Expert” has the meaning set
forth in Section 11.3.1. 
 “EXW” has the meaning set forth in INCOTERMS 2010. 

“Facility Improvements” means, with respect to a Product, any improvements or changes (a) to the Manufacturing process
used or services performed to Manufacture such Product that apply generally to all products Manufactured at the Manufacturing Facility and (b) that do not require updates to the regulatory dossiers for such Product or any other filings with any
Regulatory Authority with respect to such Product. 
 “FDA” means the United States Food and Drug Administration. 

“Feasibility Opinion” has the meaning set forth in Section 3.1.1. 

“Field” means, with respect to the WinRho SDF® product, the
therapeutic, prophylactic and diagnostic use of such Product in the Rh0(D) indication; with respect to the HepaGam B® product, the therapeutic, prophylactic and diagnostic use of such Product
in the Hepatitis B indication; and with respect to the VARIZIG® product, the therapeutic, prophylactic and diagnostic use of such Product in the Varicella-zoster hyperimmune immunoglobulins
indication. 

  
 4 

 “Finished Product Shipping Specifications” means the details of all required
import/export or customs documentation, Aptevo’s instructions for shipping and packaging each Product and such other information as is necessary for the proper shipment of finished Products under this Agreement, as provided by Aptevo to
Emergent in writing from time to time during the ordinary course of business. 
 “Firm Delivery Date” means, with respect
to each Vial in a Purchase Order, the proposed date set forth in such Purchase Order on which Emergent is expected to issue the Emergent Release Documents with respect to such Vial, which date shall be not less than six (6) months from the date
of such Purchase Order. 
 “Force Majeure” has the meaning set forth in Section 12.3. 

“Forecast” has the meaning set forth in Section 3.1.1. 

“FTE” means the equivalent of the work of one (1) duly qualified employee of Emergent full time for one (1) year
(consisting of a total of 1,950 hours per year) carrying out technology transfer work under this Agreement. Overtime, and work on weekends, holidays and the like will not be counted with any multiplier (e.g., time-and-a-half or double time)
toward the number of hours that are used to calculate the FTE contribution. The portion of an FTE billable by Emergent for one (1) individual during a given accounting period will be determined by dividing the number of hours worked directly by
said individual on the work to be conducted under the Agreement during such accounting period and the number of FTE hours applicable for such accounting period based on 1,950 working hours per calendar year. 

“Governmental Authority” means any nation or government, any state, province, municipality or other political subdivision
thereof, and any entity, body, agency, commission, department, board, bureau, court, tribunal or other instrumentality, whether federal, state, local, domestic, foreign or multinational, exercising executive, legislative, judicial, regulatory,
administrative or other similar functions of, or pertaining to, government and any executive official thereof. 
 “Included
Manufacturing Improvements” means all Facility Improvements and Platform Manufacturing Improvements. 
 “Indemnified
Party” has the meaning set forth in Section 8.3. 
 “Indemnifying Party” has the meaning set forth in
Section 8.3. 
 “Information” means information, whether or not patentable or copyrightable, in written, oral,
electronic or other tangible or intangible forms, whether or not stored in any medium that has existed, now exists or will exist, including studies, reports, records, books, contracts, instruments, surveys, discoveries, ideas, concepts, know-how,
techniques, designs, specifications, drawings, blueprints, diagrams, models, prototypes, samples, flow charts, data, computer data, disks, diskettes, tapes, computer programs or other Software, marketing plans, customer names, communications by or
to attorneys (including attorney-client privileged 

  
 5 

 
communications), memos and other materials prepared by attorneys or under their direction (including attorney work product), and other technical, financial, employee or business information or
data. 
 “Insolvency/Bankruptcy Event” shall be deemed to have occurred if a Party: (a) voluntarily consents to an
order for relief by filing a petition for relief under any bankruptcy or insolvency laws of any jurisdiction; (b) seeks, consents to or does not contest the appointment of a receiver, custodian or trustee for itself or for all or any part of
its property; (c) files a petition seeking relief under the bankruptcy, arrangement, reorganization or other debtor relief laws of any competent jurisdiction; (d) admits in writing that it is generally not paying its debts as those debts
become due; (e) gives notice to any Governmental Authority of insolvency or pending insolvency; (f) becomes “insolvent” as that term is defined under applicable fraudulent transfer or conveyance laws or comparable foreign laws;
or (g) makes an assignment for the benefit of creditors or takes any other similar action for the protection or benefit of creditors. 

“Intellectual Property” means all of the following whether arising under the Laws of the United States or of any other
foreign or multinational jurisdiction: (a) patents, patent applications (including patents issued thereon) and statutory invention registrations, including reissues, divisions, continuations, continuations in part, substitutions, renewals,
extensions and reexaminations of any of the foregoing, and all rights in any of the foregoing provided by international treaties or conventions (the foregoing, collectively, “Patents”), (b) trademarks, service marks, trade names,
service names, trade dress, logos and other source or business identifiers, including all goodwill associated with any of the foregoing, and any and all common law rights in and to any of the foregoing, registrations and applications for
registration of any of the foregoing, all rights in and to any of the foregoing provided by international treaties or conventions, and all reissues, extensions and renewals of any of the foregoing (the foregoing, collectively,
“Trademarks”), (c) Internet domain names, (d) copyrightable works, copyrights, moral rights, mask work rights, database rights and design rights, in each case, other than Software, whether or not registered, and all registrations
and applications for registration of any of the foregoing, and all rights in and to any of the foregoing provided by international treaties or conventions, (e) confidential and proprietary Information, including trade secrets, invention
disclosures, processes and know-how, in each case, other than Software, (f) intellectual property rights arising from or in respect of any Technology, and (g) rights to enforce any past, present or infringement or misappropriation of any
of the foregoing. 
 “Joint Steering Committee” has the meaning set forth in Section 2.1.3(a). 

“Latent Defect” has the meaning set forth in Section 3.6. 

“Law” means any national, supranational, federal, state, provincial, local or similar law (including common law), statute,
code, order, ordinance, rule, regulation, treaty (including any income tax treaty), license, permit, authorization, approval, consent, decree, injunction, binding judicial or administrative interpretation or other requirement, in each case, enacted,
promulgated, issued or entered by a Governmental Authority. 

  
 6 

 “Manufacture” means, with respect to a Product, the performance of all of the
manufacturing services or a portion thereof as set out in this Agreement for the manufacture of such Product, including procuring Materials, manufacturing, packaging, labeling, filling, finishing, capping, storing, inspecting, release testing,
labeling, release and stability storage and testing of such Product, and testing and release of the Materials used to make such Product. “Manufactured” and “Manufacturing” shall have comparable meanings. 

“Manufacturing Facility” means Emergent’s (or its Affiliate’s, as applicable) premises and equipment located at its
facility at 155 Innovation Drive, Wpg, Manitoba, CA or 1111 S. Paca St., Baltimore, Maryland, USA, as applicable. 
 “Manufacturing
Failure” means (i) Emergent’s failure to Deliver at least fifty percent (50%) of the aggregate quantity of all Vials of Product with respect to all Binding Purchase Orders (exclusive of those Vials used as retain samples,
those Vials used for the stability program as set forth in the Quality Agreement and those Vials Manufactured but not Delivered by agreement of the Parties) within a rolling twelve (12) month period in accordance with this Agreement (other than
where such failure is due to a Force Majeure), provided that (a) Aptevo may only make the determination as to whether such failure has occurred during the prior twelve (12) months as of the end of a calendar quarter (i.e., as of
March 31, June 30, September 30, or December 31, as applicable) and (b) Aptevo must provide Emergent notice in writing within fifteen (15) days of such determination; or (ii) a termination of this
Agreement by Emergent pursuant to Section 9.2.5. 
 “Manufacturing Fee” means, with respect to a Product, the
applicable fee set forth on Schedule A, as may be changed from time to time in accordance with Sections 3.15, 3.16 or 3.19. 

“Manufacturing Improvements” means the Facility Improvements, Platform Manufacturing Improvements and Product-Specific
Manufacturing Improvements. 
 “Master Batch Record” means, with respect to a Product, a master production and control
record containing a written description of the procedure to be followed for processing a Batch of such Product, including a complete list of all active and inactive ingredients, components, weights and measures, descriptions of drug product
containers, closures, packaging materials, and labeling and complete specifications for each, within the meaning of 21 CFR part 211.186, or its successor as in effect from time to time. 

“Materials” means, with respect to a Product, the test material, and all compounds, raw and packaging materials or substances
Manufactured, sourced or supplied by Emergent, excluding machinery and equipment, that Emergent requires to Manufacture such Product. 

“Minimum Annual Order” has the meaning set forth in Section 3.1.5. 

“Minimum Vials” means, with respect to a Product and a size (as applicable), the number of Vials with respect to such Product
and size as listed in Item 1 of Schedule B. 

  
 7 

 “Non-Conforming Product” means Product Manufactured by Emergent under this
Agreement that is not Conforming Product. 
 “Packaging Material” means, with respect to a Product, the packaging materials
for such Product as designated by Aptevo to Emergent in writing, and such other packaging materials as are necessary for Emergent to Manufacture and supply the Products and perform the 3PL Services for the Products (other than the 3PL-Only
Products). 
 “Packaging Material Baseline Inventory” means, with respect to a Product, the stock of Packaging Material
sufficient for Emergent to perform all packaging and labeling services for such Product under Sections 3.11 and 3.12, which stock shall be maintained in a quantity (i) consistent with the quantity of packaging inventory that
Emergent would normally maintain in the ordinary course of business with respect to its own product packaging inventory and (ii) consistent with the Binding Six Month Forecast. 

“Part Number” means, with respect to a Vial of Product, the unique number (as provided in writing on a list of available Part
Numbers from Emergent to Aptevo from time to time) describing the size, dosage, labeled market and other attributes of such Vial of Product. 

“Platform Manufacturing Improvements” means, with respect to a Product, any improvements or changes (a) to the
Manufacturing process used or services performed to Manufacture such Product that apply generally to all products Manufactured at the Manufacturing Facility and (b) that require updates to the regulatory dossiers for such Product or any other
filings with any Regulatory Authority with respect to such Product. 
 “Product” has the meaning set forth in the PLA. 

“Product-Specific Manufacturing Improvements” means, with respect to a Product, any improvements or changes to the
Manufacturing process used or services performed specifically to Manufacture such Product, but no other product. 

“Product-Specific IP” means all Intellectual Property rights in or to (a) release-testing assays formulated or specific
to the Products and (b) Product-Specific Manufacturing Improvements. 
 “Project Manager” has the meaning set forth in
Section 2.1.1. 
 “Purchase Order” means a document issued and signed by Aptevo, ordering a specified number of
Vials of one or more Products from Emergent. With respect to each Vial of Product ordered, each written Purchase Order will include (a) the Part Number; (b) product description; (c) the Firm Delivery Date; and (d) the Storage Facility. The Purchase
Order shall also include the Manufacturing Fee to be paid for such order pursuant to terms of this Agreement. If any terms or requirements are included in the Purchase Order that are in addition to or in conflict with the terms of this Agreement,
other than those terms set forth in this definition, then such additional or conflicting terms are of no force and effect and are superseded by the terms and requirements of this Agreement. Emergent may propose changes to the information required to
be included in a Purchase Order to Aptevo for Aptevo’s written consent, which consent shall not be unreasonably withheld or delayed. 

  
 8 

 “Purchase Order Shortfall” has the meaning set forth in
Section 3.1.4. 
 “Quality Agreement” means the Quality Agreement between Aptevo and Emergent for the Products,
effective as of the Effective Time and attached hereto at Schedule C (as may be amended or superseded from time to time by mutual agreement of the Parties or as set forth in the Quality Agreement), which specifies the respective
responsibilities for quality control and quality assurance activities consistent with cGMPs with respect to the Manufacturing of the Products. 

“Quality Department” means the department within Emergent responsible for quality assurance matters. 

“Regulatory Approval” means all technical, medical and scientific licenses, registrations, authorizations, consents and
approvals of any Regulatory Authority, necessary for the use, development, manufacture, and commercialization of a given biologic, pharmaceutical or medical device in a given regulatory jurisdiction. 

“Regulatory Authority” means the applicable Governmental Authority that has jurisdiction with respect to the Manufacture of
the Products in the Territory. 
 “Regulatory Standards” means (a) procurement and maintenance of any and all permits,
licenses, filings and certifications required by Health Canada, the FDA or other Regulatory Authorities within the Territory, and compliance with the cGMPs applicable to the Manufacturing Facility or Emergent’s processing, storage, handling or
other Manufacturing of the Materials or Products at the Manufacturing Facility, and (b) any Laws of any Governmental Authority within the Territory (including, as applicable, the Environmental Protection Agency (EPA), the Occupational Safety
and Health Administration (OSHA), the Drug Enforcement Administration (DEA) and state and local authorities), that apply to the Manufacturing Facility or Emergent’s processing, storage, handling, shipment or other Manufacturing of the Materials
or Products. 
 “Rejection Notice” has the meaning set forth in Section 3.6. 

“Release” means, with respect to a Vial of Product, the delivery of all applicable Emergent Release Documents from Emergent
to Aptevo in accordance with Section 3.4 and the issuance by Aptevo of the Aptevo Certificate of Analysis and such other Aptevo required release documents as are agreed by the Parties in writing from time to time. 

“Second Source Manufacturer” has the meaning set forth in Section 3.22. 

“Shipping Order” means a document issued by Aptevo to Emergent requesting that Emergent perform the 3PL Services in respect
of a shipment to be made by Emergent to Aptevo or a third party under this Agreement, setting out detailed information regarding the shipment, 

  
 9 

 
including the number of Vials of each Product to be shipped, the Batch from which each Vial is being requested, the shipping destination of each Vial (including the Distribution Destination) (the
“Shipping Destination”), the requested shipment date, the requested delivery date. For clarity, each Shipping Order may only name one Distribution Destination. 

“Specifications” means, with respect to a Product, the specifications required for Manufacture, including the specifications
for the applicable Materials and such Product, which specifications have, as of the Effective Time, been approved by both Parties (or are thereafter amended as agreed upon by both Parties in writing) and are set forth in the Master Batch Record.

 “Storage Facility” means, with respect to each Vial of Product, the Emergent (or its Affiliate’s) facility named in
the applicable Purchase Order at which such Vial shall be stored pending shipment. 
 “Technology” means all technology,
designs, formulae, algorithms, procedures, methods, discoveries, processes, techniques, ideas, know-how, research and development, technical data, tools, materials, specifications, processes, inventions (whether patentable or unpatentable and
whether or not reduced to practice), apparatus, creations, improvements, works of authorship in any media, confidential, proprietary or nonpublic information, and other similar materials or Information, and all recordings, graphs, drawings, reports,
analyses and other writings, and other tangible embodiments of the foregoing in any form whether or not listed herein. 

“Territory” means all countries, territories and commonwealths of the world described in Section 3.13. 

“Triggering Event” has the meaning set forth in Section 9.4. 

“VariZig” means Varicella Zoster Immune Globulin (Human). 

“Vial” means, with respect to each Product, an individual, retail-size vial of such Product (as set forth in Schedule
A). 
 “Work-in-Process” means, with respect to a Product, all Materials that Emergent has begun to Manufacture into
the relevant finished Product, but which have not yet satisfied the Specifications. 
 ARTICLE II 

GENERAL TERMS 
 2.1 Project
Management. 
 2.1.1 Project Managers. Each of the Parties shall appoint and maintain, throughout the term of this Agreement, a
project manager who shall be the main contact person for such Party, respectively, with respect to commercial or business issues under this Agreement (each, a “Project Manager”); provided, however, that a Party may designate a
replacement Project Manager from time to time upon notice to the other Party. Each Project Manager shall be 

  
 10 

 
familiar with all aspects of this Agreement and shall be available during regular business hours to discuss, and attempt to address, any questions, concerns or issues either Party may raise
regarding the Agreement. 
 2.1.2 Aptevo Representatives. Aptevo may appoint and maintain, throughout the term of this Agreement, a
product specialist who shall be permanently staffed in the Manufacturing Facility to oversee Aptevo’s responsibilities under this Agreement (the “Aptevo Representative”), provided, however, that Aptevo may designate a
replacement Aptevo Representative from time to time upon notice to Emergent. The Aptevo Representative shall (a) be an employee of, or a consultant or contractor engaged by, Aptevo or one of its Affiliates, (b) be bound to a written
confidentiality agreement, (c) comply with all rules and regulations applicable to visitors to the Manufacturing Facility, and (d) in no event be deemed an employee of Emergent or any of its Affiliates. Aptevo shall be solely liable for
the Aptevo Representative and any acts or omissions by the Aptevo Representative. Emergent shall, at no additional cost to Aptevo, provide to the Aptevo Representative a workspace, chair, telephone and high-speed internet connection for such Aptevo
Representative to carry out his or her duties. If Aptevo does not appoint and maintain a product specialist who is permanently staffed in the Manufacturing Facility, then Section 5.3.1. of the Quality Agreement shall govern Aptevo’s rights
with respect to person in plant visits. 
 2.1.3 Joint Steering Committee. 

(a) Establishment; Membership. Within thirty (30) days of the Effective Time, the Parties shall establish a joint steering
committee (the “Joint Steering Committee”) composed of an equal number of appointed representatives of each of Emergent and Aptevo, with at least one (1) appointed representative of each Party having sufficient expertise and
sufficient seniority and authority with respect to the applicable Party to make decisions with respect to manufacturing matters. A Party may change one or more of its representatives on the Joint Steering Committee at any time. One
(1) representative from each Party shall alternate in acting as the chairperson of the Joint Steering Committee for a one (1) year-long term, with Emergent’s representative chairing the Joint Steering Committee until the first
anniversary of the Effective Time. The chairperson shall not have any greater authority than any other representative on the Joint Steering Committee and shall be responsible for the following activities of the Joint Steering Committee:
(i) calling meetings of the Joint Steering Committee, (ii) preparing and issuing minutes of each such meeting within fifteen (15) days thereafter, which minutes shall not be finalized until each Party reviews and confirms the accuracy
of such minutes in writing (provided that any minutes shall be deemed approved unless a member of the committee objects to the accuracy of such minutes within thirty (30) days of the circulation of the minutes by the chairperson), and
(iii) preparing and circulating an agenda for the upcoming meeting; provided, that the chairperson shall include any agenda items proposed by the Party of which the chairperson is not a representative. The Parties may allow additional employees
to attend meetings of the Joint Steering Committee subject to the confidentiality provisions of ARTICLE VI. In addition to expertise, seniority, and authority with respect to manufacturing matters, each Party’s Joint Steering Committee
members shall collectively have sufficient expertise and sufficient seniority and authority with respect to the applicable Party to make other decisions within the scope of the Joint Steering Committee’s authority, including with respect to
clinical, regulatory and business matters. 

  
 11 

 (b) Meetings; Responsibilities. During the term of this Agreement, the Joint Steering
Committee shall meet in person or by teleconference or videoconference at least once every calendar quarter. Each Party shall be responsible for all of its own expenses incurred in connection with participating in the Joint Steering Committee
meetings. The Joint Steering Committee shall discuss and decide on the issues and questions necessary to further the purposes of this Agreement, as mutually agreed upon by the Parties in writing, and subject to Section 4 of the Quality
Agreement. Quorum for such meetings shall consist of at least one (1) member of each Party attending the meeting. Each Party will have a single vote regardless of the number of representatives of such Party in attendance and decisions shall be
made by the affirmative vote of each Party through its representatives at such meetings. Notwithstanding anything to the contrary set forth herein, the Joint Steering Committee will not have the right to make any decisions (i) in a manner that
excuses a Party from any obligation specifically enumerated under this Agreement, (ii) in a manner that negates any consent right or other right specifically allocated to a Party under this Agreement, (iii) to amend or modify this
Agreement or any of the Parties’ respective rights and obligations hereunder or (iv) in a manner that would require a Party to perform any act that would cause such Party to breach any of its obligations hereunder. 

2.2 Exclusivity. Subject to Section 2.8, during the term of this Agreement, Emergent shall be Aptevo’s sole
manufacturer of, and sole provider of all Manufacturing services with respect to, each of the Products or any variants, derivations or improved versions thereof anywhere in the world; provided, however, that the foregoing exclusivity
shall terminate immediately upon the occurrence of a Triggering Event. 
 2.3 Manufacturing and Product Quality. Subject to the terms
and conditions of this Agreement, Emergent shall Manufacture the Products for the Territory at the Manufacturing Facility and shall produce the Products in accordance with the terms hereof and the terms of the Quality Agreement in all material
respects. For clarity, Emergent may use Aptevo’s Confidential Information to perform Emergent’s obligations under this Agreement. 

2.4 Master Batch Records. Emergent shall prepare and maintain the Master Batch Records for the Manufacturing of Products at the
Manufacturing Facility. Subject to Section 4 of the Quality Agreement, Emergent may make changes to a Master Batch Record that (i) Emergent believes in its good faith judgment are required to maintain the Manufacturing Facility’s
compliance with GMP or (ii) are required by the applicable Regulatory Authority (if Emergent is so informed of such requirement by written notice from Aptevo or a Regulatory Authority). Emergent will use commercially reasonable efforts to make
changes to the Master Batch Record with ample time and consideration for required filings, as applicable, to ensure Aptevo’s relevant biologics license applications remain in compliance. 

  
 12 

 2.5 Improvements. 

2.5.1 Facility Improvements. Subject to Section 4 of the Quality Agreement, Emergent may implement Facility Improvements upon
providing written notice thereof to Aptevo, which notice shall include the timeline for implementing such Facility Improvement and an assessment of the impact of such Facility Improvement, if any, on the Products; provided that, Emergent shall
consider in good faith the extent to which such Facility Improvements would have any adverse impact on the Product, including adverse impacts on Batch yield or Product safety, efficacy, stability or shelf life, before making such Facility
Improvements. Emergent will bear all costs and expenses associated with Emergent’s implementation of any Facility Improvement. 
 2.5.2
Platform Manufacturing Improvements. Subject to Section 4 of the Quality Agreement, if Emergent seeks to implement any Platform Manufacturing Improvement, then Emergent shall present Aptevo with a written notice of such Platform
Manufacturing Improvement, including the timeline for implementing such Platform Manufacturing Improvement and an assessment of the impact of such Platform Manufacturing Improvement, if any, on the Products. Emergent may implement Platform
Manufacturing Improvements in its sole and absolute discretion, and such Platform Manufacturing Improvement shall become part of the process by which Emergent Manufactures the Products for Aptevo under this Agreement. Emergent shall bear all costs
and expenses associated with Emergent’s implementation of any Platform Manufacturing Improvement. 
 2.5.3 Product-Specific
Manufacturing Improvements. Subject to Section 4 of the Quality Agreement, if Emergent seeks to implement any Product-Specific Manufacturing Improvement (whether developed by Emergent or suggested to Emergent by Aptevo), then Emergent shall
present Aptevo with a written notice of such Product-Specific Manufacturing Improvement, including the timeline for implementing such Product-Specific Manufacturing Improvement and an assessment of the impact of such Product-Specific Manufacturing
Improvement, if any, on the Products. Both Parties must approve such Product-Specific Manufacturing Improvements in writing. All implemented Product-Specific Manufacturing Improvements shall become part of the process by which Emergent Manufactures
the Products for Aptevo under this Agreement. Aptevo shall pay all costs incurred by Emergent for implementing Product-Specific Manufacturing Improvements. 

2.5.4 Effects of Improvements. To the extent the implementation of any Facility Improvement or Platform Manufacturing Improvements by
Emergent result in a Batch containing any Non-Conforming Product, Emergent shall Credit the Manufacturing Fee for the applicable Vials of such Non-Conforming Product. To the extent any Platform Manufacturing Improvements or Product-Specific
Manufacturing Improvements require Aptevo to update or change the regulatory dossiers for its Products during the Term, Emergent shall provide all applicable updated hyperimmune regulatory dossier pages for Aptevo to review. Such pages are provided
as proposals only and Aptevo shall submit such pages or portions thereof to Regulatory Authorities at its sole discretion and bear the full responsibility for such filings. Emergent shall provide complete, true and accurate information in such
proposed dossier pages, but Aptevo is ultimately responsible for submitting and maintaining dossiers associated with its Regulatory Approvals for the Products and for the completeness and accuracy of such dossiers. 

  
 13 

 2.6 Licenses 

2.6.1 License to Emergent. For clarity, to the extent not already licensed under the terms of the PLA, during the term of this
Agreement, and subject to the terms and conditions of this Agreement, Aptevo grants to Emergent a non-exclusive, worldwide, sublicenseable and royalty-free license, under any Intellectual Property owned or
controlled by Aptevo or any of its Affiliates (including all Product-Specific IP) (“Aptevo IP”), solely to perform the services and to comply with Emergent’s obligations under the terms and conditions of this Agreement and the
Quality Agreement. 
 2.6.2 License to Aptevo. For clarity, to the extent not already licensed under the terms of the PLA, during the
term of this Agreement, and subject to the terms and conditions of this Agreement, Emergent grants to Aptevo a non-exclusive, royalty-free, worldwide, non-transferable (except as provided in this Section 2.6.2 and for certain assignments
as provided in Section 12.4) license, under the Manufacturing Technology and the Included Manufacturing Improvements, to make, have made, use, sell, offer to sell, import and otherwise commercialize the Products, solely within the Field,
provided that Aptevo may only exercise (and the other members of the Aptevo Group may only exercise) the rights to make and have made the Products through Emergent as contemplated by this Agreement or through a CMO pursuant to and in
accordance with the PLA. 
 2.6.3 Necessity; Trade Secrets; Confidentiality. Aptevo acknowledges and agrees that the Manufacturing
Technology and the Included Manufacturing Improvements are the proprietary, confidential know-how of Emergent of which some portions are further protected as trade secrets (as such term is defined in the Economic Espionage Act of 1996, 18 U.S.C.
§ 1839 or other applicable Law). Aptevo shall consider the Manufacturing Technology and the Included Manufacturing Improvements and all trade secrets contained therein as Confidential Information under this Agreement, shall strictly adhere to
its confidentiality obligations under this Agreement with respect to such Information, and hereby acknowledges and agrees that the remedy at Law for any breach of this Section 2.6.3 would be inadequate and that Emergent shall be entitled
to injunctive relief, without the requirement of posting any bond or other security, in addition to any other remedy it may have upon breach of any provision of this Section 2.6.3, provided that Emergent shall not seek an
injunction preventing the delivery of the Products into the stream of commerce unless such Products contain or otherwise transmit (in their packaging, labeling or otherwise) the Manufacturing Technology or the Included Manufacturing Improvements or
any other Confidential Information of Emergent. 
 2.6.4 Other Licenses. Aptevo is solely responsible for providing licenses to all
Intellectual Property (other than the Licensed IP) necessary for Emergent to perform services under this Agreement, except for such licenses as would be required for any Third Party Intellectual Property rights that would be infringed by any
Facility Improvement or Platform Manufacturing Improvement. To the extent Emergent becomes aware of any Third Party Intellectual Property that is needed to perform the Manufacturing services contemplated herein, Emergent shall provide written notice
of such requirement to Aptevo. 

  
 14 

 2.6.5 No Other Licenses and Rights. Except as expressly provided in this
Section 2.6, no other license or right is granted to any member of the Aptevo Group under this Agreement, whether expressly or by implication, estoppel, statute or otherwise. Neither Aptevo, nor any member of the Aptevo Group, shall have
any right to file, prosecute, maintain, enforce or defend any Intellectual Property rights or registrations thereof for any of the Licensed IP, Manufacturing Technology or Included Manufacturing Improvements, and neither Emergent, nor any member of
the Emergent Group, shall have any right to file, prosecute, maintain, enforce or defend any Intellectual Property rights or registrations thereof for any of the Aptevo IP. 

2.6.6 No Obligation to Obtain or Maintain Intellectual Property. Neither Emergent, nor any member of the Emergent Group, is
obligated to file, prosecute, maintain, enforce or defend any Intellectual Property rights or registrations thereof for any of the Licensed IP, Manufacturing Technology or Included Manufacturing Improvements, provided that during the
term of this Agreement, Emergent shall use commercially reasonable efforts to maintain the secrecy of its trade secrets within the Manufacturing Technology and the Included Manufacturing Improvements. Neither Aptevo, nor any member of the Aptevo
Group, is obligated to file, prosecute, maintain, enforce or defend any Aptevo IP. 
 2.7 Arising Intellectual Property;
Improvements. 
 2.7.1 As between the Parties, Aptevo will own all Product-Specific IP, whether conceived, made or reduced to practice by
Aptevo, Emergent, any of their respective Affiliates, or any of their respective employees or agents, alone or jointly with others or jointly with the other Party, any of its Affiliates or any of its employees or agents. Emergent, on behalf of
itself and its Affiliates, hereby assigns to Aptevo all right, title and interest in and to the Product-Specific IP and all Intellectual Property rights therein. 

2.7.2 As between the Parties, Emergent will own any and all improvements and enhancements made to, and derivatives of, any of Background
Emergent IP or the Manufacturing process for any of the Products (including Included Manufacturing Improvements and all Intellectual Property Rights therein), whether such improvements, enhancements or derivatives were conceived, made or reduced to
practice by Aptevo, Emergent, any of their respective Affiliates or any of their respective employees or agents, alone or jointly with others or jointly with the other Party, any of its Affiliates or any of its employees or agents (except for
Product-Specific IP) (“Emergent-Owned IP”). Aptevo, on behalf of itself and its Affiliates, hereby assigns to Emergent all right, title and interest in and to the Emergent-Owned IP and all Intellectual Property rights therein. 

2.7.3 Each Party will provide all further cooperation which the other Party reasonably determines is necessary to give effect to the ownership
of the Emergent-Owned IP and Product-Specific IP set forth in Section 2.7.1 and Section 2.7.2 and to ensure the owning Party the full and quiet enjoyment of such Emergent-Owned IP and Product-Specific IP (as applicable), including
executing and delivering further assignments, consents, releases and other commercially reasonable documentation, and providing good faith testimony by affidavit, declaration, deposition, in person or other proper means and otherwise assisting such
other Party in support of any effort by such owning Party to establish, perfect, defend or enforce its rights in such Emergent-Owned IP or Product-Specific IP (as applicable). 

  
 15 

 2.8 Delegation. Emergent may use any of its Affiliates or other third parties to fulfill
any of its obligations under this Agreement in its sole discretion, provided that Emergent shall seek Aptevo’s written permission for any delegation for which permission is required under the Quality Agreement, which permission shall not be
unreasonably withheld. To the extent Emergent retains subcontractors, such subcontractors are required to perform to the standards set forth in this Agreement and Emergent shall maintain responsibility for such subcontractors’ performance. 

2.9 Invoices. All amounts invoiced under this Agreement shall be payable within forty-five (45) days of the invoice
recipient’s receipt of such invoice. 
 ARTICLE III 

MANUFACTURING SERVICES 
 3.1
Purchases. 
 3.1.1 Forecasts. Within thirty (30) days after the Effective Time, Aptevo will provide Emergent with a
written, non-binding forecast of Batch purchases by Product by month for the following twenty-four (24) months; provided that the number of Vials of each Product forecasted for each month will be specified in integer multiples of the Minimum
Batch Size as set forth on Schedule B (a “Forecast”), the first six (6) months of which shall be binding on Aptevo and cannot be changed in subsequent Forecasts (a “Binding Six Month Forecast”) and months seven
(7) through nine (9) of which may be increased or decreased by Aptevo by no more than twenty-five percent (25%) of the number of Vials of Product (on a Product-by-Product basis) for the same month in the immediately preceding
submitted Forecast (each, a “Semi-Binding Forecast”). By the end of each month thereafter, Aptevo will provide a new Forecast for the twenty-four (24) months commencing with the very next calendar month (a rolling forecast),
the first six (6) months of which shall be a Binding Six Month Forecast and months seven (7) through nine (9) of which will be a Semi-Binding Forecast. If Aptevo does not provide a new Forecast by the end of a month, the last Forecast
provided shall become the new and most recent Forecast, and the Binding Six Month Forecast shall be comprised of the second through seventh months of the prior Forecast and the Semi-Binding Forecast shall be comprised of the eighth through tenth
months of the prior Forecast. The Forecast must include sufficient detail to identify planned purchases per month for twenty four (24) months. Upon receipt of each Forecast, Emergent will provide an indication of Emergent’s ability to meet
such Forecast (a “Feasibility Opinion”) and a proposed schedule of Manufacturing dates for the following six (6) months to be updated on a monthly basis. With respect to Emergent, all Forecasts and Feasibility Opinions are for
planning purposes only and do not bind Emergent to Manufacture, except to the extent set forth in Section 3.1.2 below. The Project Managers, or their designees within each Party’s supply chain organization management, shall meet
monthly in person or by teleconference to discuss the Forecast and the Binding Six Month Forecast and the Semi-Binding Forecast. 

  
 16 

 3.1.2 Purchase Orders; Acceptance. All purchases of Manufacturing services under this
Agreement shall be effected solely pursuant to a Purchase Order and in accordance with the terms of this ARTICLE III. Except with the written approval of Emergent, Aptevo shall submit each Purchase Order as far in advance of the Firm Delivery
Date named in such Purchase Order as possible, but in any event at least six (6) months before the Firm Delivery Date named in such Purchase Order. Emergent shall accept timely Purchase Orders that are in conformance with the applicable
Feasibility Opinion, and Emergent shall use commercially reasonable efforts to accept Purchase Orders in excess of the Binding Six Month Forecast. During each year, Emergent shall accept Purchase Orders representing at least the Minimum Annual Order
for such year, and Emergent shall use commercially reasonable efforts to accept Purchase Orders in excess of the Minimum Annual Order. Only those Purchase Orders accepted by Emergent by written notification to Aptevo after receipt of such Purchase
Order shall be Binding Purchase Orders. In the event Emergent does not respond to a Purchase Order within fifteen (15) days after receipt thereof, Emergent shall be deemed to have accepted such Purchase Order. Emergent will use commercially
reasonable efforts to issue to Aptevo the Emergent Release Documents with respect to all Product ordered under a Binding Purchase Order on the Firm Delivery Date included in such Binding Purchase Order. 

3.1.3 Cancellations. Aptevo may reduce the number of Vials forecasted for any month under a Binding Six Month Forecast or a
Semi-Binding Forecast by providing notice to Emergent in writing, provided that, with respect to all such reductions under a Binding Six Month Forecast, and all such reductions under a Semi-Binding Forecast in excess of twenty-five percent
(25%) of the number of Vials set forth therein, Aptevo shall, in each case, (a) pay a fee equal to twenty-five percent (25%) of the applicable Manufacturing Fee per canceled Vial if such cancellation occurs with respect to quantities
of Product forecast in the fourth, fifth or sixth month of the immediately preceding Binding Six Month Forecast or the seventh, eighth or ninth month of the immediately preceding Semi-Binding Forecast, (b) pay a fee equal to fifty percent
(50%) of the applicable Manufacturing Fee per canceled Vial if such cancellation occurs with respect to quantities of Product forecast in the third or fourth month of the immediately preceding Binding Six Month Forecast and (c) pay a fee
equal to 100% of the applicable Manufacturing Fee per canceled Vial if such cancellation occurs with respect to quantities of Product forecast in the second month of the immediately preceding Binding Six Month Forecast. Notwithstanding the
foregoing, Aptevo may reduce the number of Vials forecasted for any month, or be released from its purchase obligations under a Binding Purchase Order (and Emergent shall be released from its Manufacturing and Delivery obligations under such Binding
Purchase Order), if such reduction or cancellation arises primarily from (i) material adverse inspection or audit findings at any Manufacturing Facility, including findings by a Regulatory Authority, or (ii) recalls, Product withdrawals,
field actions or other corrective actions, except to the extent such recall, Product withdrawal, field action or other corrective action was caused solely by Aptevo. At the end of each month, Aptevo shall pay the Manufacturing Fee for any amount of
Product that was forecasted for such month under a Binding Six Month Forecast but neither purchased under a Purchase Order for such month nor canceled pursuant to this Section 3.1.3. 

  
 17 

 3.1.4 Filling Purchase Orders. Emergent shall fill Binding Purchase Orders,
provided that Emergent shall be under no obligation to Manufacture the Products set forth in a Binding Purchase Order if: (i) Aptevo has been in default of its payment obligations hereunder, under the TSA or under any other
Ancillary Agreement for more than forty-five (45) days from the date on which Emergent provided Aptevo with written notice of such default (which notice period shall be tolled during any bona fide dispute regarding such invoice); or
(ii) Aptevo is in material breach of any of its representations, warranties, covenants, or obligations hereunder, under the TSA or under any other Ancillary Agreement. Aptevo acknowledges and agrees that, when filling a Binding Purchase Order,
Emergent may provide a number of Vials between ninety-five percent (95%) and one hundred five percent (105%) of the number of Vials ordered in such Purchase Order, (which number of Vials ordered in such Purchase Order, for purposes of
determining the percentage of Vials provided by Emergent, shall not include those Vials used as retain samples and those Vials used for the stability program as set forth in the Quality Agreement or otherwise agreed to by the Parties). Without
limiting the foregoing, if Emergent provides fewer Vials of Conforming Product than the number of Vials ordered in a particular Binding Purchase Order (a “Purchase Order Shortfall”), then Aptevo may require Emergent to make up such
Purchase Order Shortfall in a subsequent Batch. 
 3.1.5 Minimum Annual Order. Each year (such year beginning and ending on an
anniversary of the Effective Time), Aptevo shall purchase at least the minimum number of Batches of each Product as set forth in Item 2 of Schedule B (the “Minimum Annual Order”). If, at the end of a given year, Aptevo has
not purchased the Minimum Annual Order, Emergent shall invoice Aptevo for the difference between Aptevo’s purchases for that year and what Aptevo would have paid for the Minimum Annual Order during that year, provided that such invoice shall be
reduced pro rata in to the extent Emergent could not perform services under this Agreement due to a Force Majeure. On the second, fourth, sixth, and eighth anniversary of the Effective Time, Aptevo may change the Minimum Annual Order of each Product
by written notice to Emergent, which new Minimum Annual Order shall not become effective until ninety (90) days after such notice is provided. The Parties agree that Aptevo is not obligated to purchase a minimum number of Vials pursuant to this
Agreement other than pursuant to the terms of this Section 3.1.5, provided; however, that, with respect to orders for VariZig, Aptevo shall purchase sufficient Vials of VariZig finished product in order to consume the VariZig bulk
product ordered by Aptevo within eighteen (18) months after the Manufacture of such bulk product. If VariZig bulk product is not consumed during this eighteen (18) month period (through further Manufacture into finished product), Emergent
shall invoice Aptevo on a pro rata basis for the price Aptevo would have paid had Emergent Manufactured such remaining VariZig bulk product into Vials. For clarity, the Parties agree and understand that once VariZig plasma is thawed and a Batch of
VariZig bulk product is Manufactured, it is capable of being frozen and stored as bulk intermittently in conformance with the Master Batch Record. 

3.2 Manufacturing. Subject to Section 2.8, as agreed between the Parties pursuant to the Quality Agreement, Emergent shall
maintain the Master Batch Records related to the Manufacturing of Products under this Agreement. Before initiating the Manufacture of any Product, Emergent shall forward a copy of the then-current Master Batch Record to Aptevo. Emergent shall use
commercially reasonable efforts to Manufacture the applicable Products 

  
 18 

 
using the Materials at the Manufacturing Facility in accordance with the applicable Master Batch Record, any and all Applicable Law, the applicable Acceptance Criteria, cGMPs, the Quality
Agreement, and Emergent’s quality assurance and quality control practices. The Products shall not be Manufactured at a facility other than at the Manufacturing Facility without the prior written consent of Aptevo. 

3.3 Storage, Use and Segregation of Work-in-Process and Product. Emergent shall own all Work-in-Process and shall label and store all
Work-in-Process and Products in its possession until Delivery of the Products in accordance with this ARTICLE III and any storage instructions provided by Aptevo. Without limiting the foregoing, Emergent shall use commercially reasonable
efforts to store Products in labeled, segregated, temperature controlled storage location with appropriate security access restrictions, and in accordance with the Master Batch Record, cGMPs, the Quality Agreement and Emergent’s quality
assurance and quality control practices. 
 3.4 Release Documents. Emergent shall prepare the Emergent Release Documents, and other
information required by Section 3.9 of the Quality Agreement, specific to each Batch, and shall use commercially reasonable efforts to submit them to Aptevo, the Aptevo Representative (if applicable) or Aptevo’s other designated
representatives as set forth in the Quality Agreement. Notwithstanding the foregoing, the Parties acknowledge and agree that investigations and deviations may require additional time and impact timelines for completion of the Emergent Release
Documents. Emergent Release Documents shall not be considered final unless and until Emergent’s Quality Department has performed a review thereof. Aptevo shall use commercially reasonable efforts to issue the Aptevo Certificate of Analysis and
such other Aptevo required release documents as are agreed by the Parties in writing from time to time for each Batch of Product within fifteen (15) days after its receipt of the Emergent Release Documents from Emergent. 

3.5 [Reserved] 
 3.6 Product
Inspection; Acceptance. Within fifteen (15) days after Aptevo’s receipt of the Emergent Release Documents for a Batch, Aptevo shall determine whether or not such Batch meets the Acceptance Criteria or is otherwise Non-Conforming
Product. For clarity, during such fifteen (15) day period, Aptevo shall have the right to inspect the Product for damage or to determine if it is Non-Conforming Product. If within such fifteen (15) day period, Aptevo makes a determination
that any Vial of Product in such Batch does not meet the Acceptance Criteria, or is otherwise Non-Conforming Product (in each case, in accordance with the acceptance procedures set forth in the Quality Agreement, if any), then Aptevo shall have the
right to reject such Batch in its entirety and shall notify Emergent in writing within such fifteen (15) day period, in each case, as set forth in the Quality Agreement (a “Rejection Notice”). If Aptevo does not submit
Rejection Notice within such fifteen (15) day period, then such Batch will be deemed to meet the Acceptance Criteria, be Conforming Product and have been accepted by Aptevo, except for Latent Defects as provided in this Section 3.6.
Notwithstanding any acceptance procedure, if any, set forth in the Quality Agreement, if any Product is Non-Conforming Product for reasons that are hidden or latent and not reasonably capable of being

  
 19 

 
discovered by Aptevo, then it shall be deemed a “Latent Defect.” Aptevo shall promptly notify Emergent in writing of such Latent Defect by the earlier of (a) thirty
(30) days after the date Aptevo discovered or should have discovered the Latent Defect and (b) ninety (90) days after Release, including a detailed explanation of the Latent Defect in question. If Aptevo fails to notify Emergent of a
Latent Defect within such period, then such Batch will be deemed to meet the Acceptance Criteria, be Conforming Product and have been accepted by Aptevo. 

3.7 Emergent Liability for Non-Conforming Batches. If, following a Rejection Notice or any notice to Emergent of any Latent Defect, it
is determined by agreement of the Parties (or in the absence of such agreement, by a qualified and independent laboratory selected jointly by Emergent and Aptevo as set forth in Section 8) that any Product Delivered to Aptevo is
Non-Conforming Product and such non-conformance was not caused by Emergent’s negligence, willful misconduct, failure to follow the Master Batch Record or failure to follow cGMP, then Emergent shall have no liability to Aptevo with respect to
such Product and Aptevo shall pay for such Product and for the fees associated with any dispute regarding the Product (including arbitrator and third-party laboratory fees). Such Product shall be treated in all other respects under this Agreement as
though it is Conforming Product. However, if such non-conformance was caused by Emergent’s negligence, willful misconduct, failure to follow the Master Batch Record or failure to follow cGMP, then Emergent shall (i) dispose of such
Non-Conforming Product and (ii) as soon as it is commercially practicable to do so, replace such Non-Conforming Product with Conforming Product at Emergent’s sole cost and expense if Aptevo has paid for the Non-Conforming Product.
Notwithstanding anything to the contrary contained herein, delivery of replacement Conforming Product shall be Aptevo’s sole and exclusive remedy with respect to the Non-Conforming Product, and in furtherance thereof Aptevo waives all other
remedies at law or in equity. 
 3.8 Cooperation in Investigations; Disposition of Non-Conforming Product. Subject to the Quality
Agreement, each Party shall act in good faith and shall cooperate with the other Party, with any qualified independent Third Party laboratory in connection with an investigation, and with the arbitrator, as to the existence of or source of
nonconformity with respect to a Product supplied under this Agreement. In testing a Product, any independent Third Party laboratory shall use analytical testing methods as agreed upon by the Parties. Emergent shall dispose of any Non-Conforming
Product in accordance with all Applicable Laws with respect to such disposal, at Emergent’s cost if Emergent was liable for the nonconformity in accordance with Section 3.7 and at Aptevo’s cost if Emergent was not liable for
the nonconformity in accordance with Section 3.7. 
 3.9 Withdrawals and Recalls. 

3.9.1 Notification and Investigation. In the event that either Party believes a recall or withdrawal of a Product may be necessary or
appropriate, such Party shall promptly notify the other Party in writing and the procedures for, and responsibilities of the Parties with respect to, all such recalls or withdrawals will be as set forth the Quality Agreement. 

  
 20 

 3.9.2 Costs of Recall. Emergent shall reimburse Aptevo for all reasonable costs incurred
by Aptevo in implementing a recall or withdrawal of Product resulting from the Delivery of Non-Conforming Product where such non-conformance was caused by Emergent’s negligence, willful misconduct, failure to follow the Master Batch Record or
failure to follow cGMP. If the recall or withdrawal is required for any reason not specified in the preceding sentence, then all costs of the Parties incurred in implementing the recall or withdrawal of Product shall be borne by Aptevo. Any dispute
between the Parties as to which Party is responsible for the costs of a recall or withdrawal will be governed by the laboratory investigation procedures set forth in Section 3.8 and the dispute resolution mechanism set forth in
ARTICLE XI. 
 3.9.3 Customer Complaints. Emergent and Aptevo will cooperate in the reporting, investigation and evaluation of
customer complaints as set forth in the Quality Agreement. 
 3.10 Title and Risk of Loss. Title to each Vial in a Batch and risk of
loss with respect to each Vial in a Batch shall pass to Aptevo upon Delivery of such Vial. 
 3.11 Packaging. Emergent shall use
commercially reasonable efforts to purchase and maintain the Packaging Material Baseline Inventory in support of the Binding Six Month Forecast per Section 3.1.1. If Aptevo designates any change to be made to any aspect of such Packaging
Material (including a change in label, format, raw material, or other changes) such that Emergent’s existing stock of Packaging Materials in support of the Binding Six Month Forecast becomes obsolete and such that Emergent is unable to
reallocate such Packaging Materials for other products, then Emergent shall invoice Aptevo for its reasonable out-of-pocket costs incurred in destroying any such Packaging Material Baseline Inventory and reasonable out-of-pocket purchase price for
such obsoleted inventory, provided that Aptevo shall have no obligation to pay for any such Packaging Materials in excess of the quantities necessary to fill orders as set forth in the Binding Six Month Forecast. 

3.12 Labeling. For each Product that is Manufactured under this Agreement, Aptevo shall provide Emergent with labeling specifications,
which shall include date of manufacture or expiration as required, Batch-specific identification and any necessary artwork and engineering drawings related thereto. All labeling specifications submitted by Aptevo shall comply with all Applicable
Laws and Regulatory Standards. Notwithstanding Emergent’s acceptance of Aptevo’s labeling specifications, Emergent shall not be responsible for any loss or liability incurred by Aptevo or any third party resulting from Emergent’s
compliance with Aptevo’s labeling specifications. 
 3.13 New Jurisdictions. This Agreement contemplates Emergent’s
provision of services with respect to the jurisdictions in which the Products are currently approved for commercial sale as of the Effective Time. If Aptevo intends to distribute Products in additional jurisdictions in which it did not distribute
such Product as of the Effective Time, and if Aptevo desires for Emergent to Manufacture or otherwise provide services related to such Product for such additional jurisdiction under this Agreement, the Parties will negotiate in good faith to

  
 21 

 
amend this Agreement to integrate such additional jurisdictions as appropriate. Such amendments may contemplate changes in price as well as changes to such Product’s Specifications, as
applicable. Any such changes shall be agreed by both Parties in writing before becoming effective. Aptevo will not otherwise have any right to make or have made such Product, or perform or have performed services related to such Product for any such
additional jurisdiction. 
 3.14 Price and Payment Terms. The price to be paid by Aptevo to Emergent for Manufacturing, all
associated services contemplated by this Agreement and any additional specified activities shall be as identified in Schedule A and E, which prices may be changed in accordance with Section 3.15, 3.16 or 3.19.
Emergent shall invoice Aptevo for each Batch of Product on Delivery of such Batch, and as otherwise set forth in Schedule A or E for activities other than Manufacturing. 

3.15 Automatic Pricing Adjustments. Commencing on the first anniversary of the Effective Time and on each anniversary of the Effective
Time thereafter, the prices set forth in Schedule A or E (as modified from time to time pursuant to Section 3.16 or 3.19) may be increased by greater of (i) three percent (3%) or (ii) the percentage
change in the index as described below, which increase shall be effective upon written notification from Emergent to Aptevo. Any changes to the price will be based on the percentage change in the Industrial Product Price Index by North American
Industry Classification System (NAICS) 329-0077 in the category Pharmaceutical and Medicine Manufacturing [3254]. For purposes of the percentage change calculation, the index value for the preceding December and the December prior will be used. 

3.16 Other Pricing Adjustments. 

3.16.1 Emergent may increase the pricing on Schedule A if a significant increase in direct manufacturing costs (being a verifiable
increase) occurs due to a change in the cost of any specialty source plasma or chromatography resin used in the Manufacturing of a Product, due to a change required by or on behalf of Aptevo or due to a Manufacturing Improvement pursuant to
Section 2.5. Emergent will notify Aptevo in writing, will not increase the applicable pricing on Schedule A until ninety (90) days after such notification to Aptevo and, subject to confidentiality obligations to third
parties, will provide suitable justification and verification data for any such increase or decrease prior to any change in pricing. 

3.16.2 Emergent may alter the pricing on Schedule A or E due to changes in the US dollar (USD) to Canadian dollar (CAD) foreign
exchange rate, which exchange rate shall be determined at the end of each calendar quarter (March 31, June 30, September 30 and December 31) as provided by the Bank of Canada. To the extent that the foreign exchange rate
varies from the USD-to-CAD rate published by Bank of Canada as of the Effective Time, Emergent shall adjust the pricing on Schedule A and E for the next calendar quarter in accordance with the Foreign Exchange Adjustment Schedule
included on Schedule A. 

  
 22 

 3.16.3 Thirty (30) days before the fifth anniversary of the Effective Time, Emergent and
Aptevo shall re-negotiate the prices set forth on Schedules A and E on a per-stock keeping unit basis in good faith, which re-negotiated prices shall be effective as of the fifth anniversary of the Effective Time, and which
re-negotiated prices shall not be in excess of fifteen percent (15%) higher or fifteen percent (15%) lower than the prices would have been as of immediately after the fifth anniversary of the Effective Time pursuant to the increases
contemplated in Sections 3.14, 3.15.1, 3.15.2 and 3.18. If Emergent and Aptevo cannot agree on such prices by the fifth anniversary of the Effective Time, then they shall resolve the dispute pursuant to the terms of
Section 11.3. 
 3.17 General Payment Terms. All costs or fees related to bank deposits or wire transfers shall be paid
by Aptevo. Any and all late payments shall be subject to the payment of interest at the lesser of the rate of 12.0% (twelve percent) per annum or the highest rate permitted by Applicable Law. In addition to any other remedies Emergent may have in
the event Aptevo does not pay an outstanding, overdue invoice for more than forty-five (45) days from the date on which Emergent provided Aptevo with written notice of such default (which notice period shall be tolled during any bona fide
dispute regarding such invoice), Emergent shall be entitled to refuse to perform any of the services contemplated by this Agreement, in its sole discretion, until all or an agreed upon portion of the aggregate amount owing has been paid, which
refusal shall not be considered a Manufacturing Failure, nor shall Emergent’s non-performance pursuant to this Section 3.17 be factored in to the analysis for determining whether a Manufacturing Failure has occurred under the
definition of Manufacturing Failure in ARTICLE I. 
 3.18 Payment without Deductions. All fees specified hereunder are
expressed as net amounts and shall be paid by Aptevo free and clear of, and without reduction for, any withholding taxes. Aptevo shall, upon request, provide Emergent with official receipts issued by the appropriate taxing authority or such other
evidence as may be reasonably requested by Emergent to establish that such taxes have been paid. 
 3.19 Stability Testing. Emergent
shall perform ongoing stability testing program services related specifically to the Products, as described in Section 3.6 of the Quality Agreement, subject to Aptevo’s timely payment of the applicable fees for such services outlined on
Schedule A. From time to time, Aptevo may reasonably request that Emergent revise its stability testing program for the Products, in which case the Parties shall negotiate in good faith with according adjustments to the pricing for such
services outlined on Schedule A. Any such changes shall be agreed by both Parties in writing before becoming effective. 
 3.20
Regulatory Audits. Aptevo shall bear all cost and expense related to any audit of the Manufacturing Facility conducted by a Governmental Authority that is (i) specific to the 3PL-Only Products or specific to any Product under this
Agreement or (ii) a general GMP audit with respect to 3PL-Only Products or any Product under this Agreement conducted by a Governmental Authority other than those in the United States or Canada, provided that Emergent shall bear all cost and
expense related to any audit of the Manufacturing Facility that is a general audit of Emergent’s Manufacturing process. Emergent shall make the Manufacturing Facility and the relevant records available for such audits to the extent set forth in
the Quality Agreement (to the extent Emergent is not bound by confidentiality restrictions with third parties with respect to such records). 

  
 23 

 3.21 Disposal or Maintenance of Products and Data. Except as necessary for Manufacturing
or as otherwise required under this Agreement, Emergent shall not dispose of any Products in any form or at any stage of Manufacturing without the prior written approval of Aptevo. Emergent shall maintain and keep complete and accurate documentation
of all validation data, stability testing data, Batch Records, quality control and laboratory testing and any other data required under cGMPs and in conformance with Emergent’s document retention policies. Notwithstanding the foregoing,
Emergent may dispose of Products and documentation in the event that such items have been stored for a forty-eight (48) month period, Emergent has provided Aptevo with notice of its intent to dispose of such items, and Aptevo has not responded
to such written notice within three (3) months. 
 3.22 Second Source. Aptevo may request in writing that Emergent allow a
specific CMO (as such term is defined in the PLA) to serve as a second manufacturing source for the Products (such CMO, the “Second Source Manufacturer”). Emergent may, in its sole discretion, comply with such request, in which
case: 
 3.22.1 Emergent may require such CMO to be subject to certain requirements or obligations; 

3.22.2 To the extent not already licensed under the terms of the PLA, Emergent shall grant to Aptevo a non-exclusive, royalty-free, worldwide,
non-transferable license, under the Manufacturing Technology and the Included Manufacturing Improvements in the form in which such Manufacturing Technology and Included Manufacturing Improvements exist at the time of such grant, to make and have
made the Products within the Field, solely by the Second Source Manufacturer; 
 3.22.3 Emergent shall provide reasonable assistance in the
transfer of the Manufacturing Technology to the Second Source Manufacturer in a manner and at a rate to be negotiated by Emergent and Aptevo; and 

3.22.4 Aptevo shall bear all costs associated with establishing the Second Source Manufacturer. 

3.23 Delivery Failures. If Emergent fails to Deliver at least eighty-five percent (85%) of the aggregate quantity of all Products
with respect to all Binding Purchase Orders within a rolling 12 month period in accordance with this Agreement or if Emergent fails to issue the Emergent Release Documents for at least eighty percent (80%) of the quantity of Vials ordered under
a Binding Purchase Order within thirty (30) days after the Firm Delivery Date in such Binding Purchase Order, then one (1) executive vice president-level representative (or more senior representative, from Aptevo) from each Party shall
meet in person or via teleconference to discuss such failures. 

  
 24 

 ARTICLE IV 

PACKAGING SERVICES FOR IXINITY 
 Emergent and
Aptevo shall enter into an agreement substantially in the form attached as Schedule D for the provision of packaging services for IXINITY. 

ARTICLE V 
 LOGISTICS SERVICES 

5.1 Scope. Aptevo hereby engages Emergent to be its provider of the logistics services set forth on the attached Schedule E (the
“3PL Services”). For purposes of this ARTICLE V, “Products” shall also include 3PL-Only Products. Although Emergent may provide additional related services to Aptevo for a period of time under the TSA, the 3PL
Services that Emergent shall provide under this Agreement are strictly limited to such services as are specified herein. If at any point Aptevo has terminated this Agreement with respect to the 3PL Services for a given Product, Emergent shall
deliver such Product to Aptevo EXW (Manufacturing Facility) upon Delivery. 
 5.2 Shipment of Products. Except for deliveries made
under quarantine on terms and conditions agreed by the Parties in writing from time to time, Emergent shall not ship a Product until: (a) the applicable Release of such Product (except for 3PL-Only Products); (b) such Product has been
approved and released for shipment by the applicable Governmental Authority (if applicable); and (c) Emergent has received from Aptevo a Shipping Order for such Product. Emergent shall thereafter cause the applicable Product to be delivered to
the Shipping Destination EXW (Storage Facility), using Aptevo’s shipping accounts, per the terms of Schedule E. If a Shipping Order requires a Product to be exported out of the applicable country of origin, Aptevo shall be the exporter
of record for such Product and shall be responsible for complying with all customs requirements and export Laws of the applicable jurisdiction. Aptevo shall also be the importer of record (where applicable) for such Products and shall be responsible
for complying with all customs requirements and import Laws of the applicable country. Aptevo shall pay all associated duties, taxes and costs for importing and exporting Products under this Agreement. Each shipment of the Product shall be
accompanied by an Aptevo Certificate of Analysis, a bill of lading prepared by Emergent, and any other documents required by Regulatory Standards and reasonably requested by Aptevo. 

5.3 Export Documentation. To the extent required to carry out a Shipping Order, Emergent shall prepare such documents as are necessary
for the applicable Regulatory Standards and other regulations pertaining to import and export of the applicable Products, provided, however, that Aptevo is solely responsible for providing Emergent with the correct forms of each
document and furnishing the necessary information required by each document, ensuring the compliance of all such documents with the applicable regulations and Aptevo shall solely bear the risk of any loss of or damage to Products, and all other
liability, due to non-compliance with applicable import or export Laws, other than any such risk of loss or damage to the Products resulting solely from Emergent’s failure to follow the Finished Product Shipping Specifications or
Emergent’s intentional misconduct or gross negligence. 

  
 25 

 5.4 Price and Payment Terms. The price to be paid by Aptevo to Emergent for 3PL Services
shall be as identified in Schedule A. The price to be paid by Aptevo to Emergent for each Shipping Order of Product shall be as identified in Schedule E. 

5.5 Delivery Loss. In the event of partial or full loss or non-delivery of a Product, the Parties will cooperate to ensure that
notification and follow-up with the involved ground and air carriers and customs or other warehouses is made in order to determine the cause of such partial loss, full loss or other non-delivery, including if such missing Product can be located. The
responsibility for such partial or full loss or non-delivery of a Product rests with Aptevo following Delivery thereof, except that Emergent shall be responsible for such full or partial loss as was caused by Emergent’s failure to follow the
Finished Product Shipping Specifications or Emergent’s intentional misconduct or gross negligence. For any Product which is not recovered or which is damaged or defective due to acts or omissions of the carrier, the Parties shall negotiate a
schedule for the Manufacturing of additional Product by Emergent at Aptevo’s cost. 
 ARTICLE VI 

CONFIDENTIALITY 
 6.1
Confidentiality Obligations under the SDA. The Parties agree and acknowledge that this Agreement is an Ancillary Agreement and that any Confidential Information exchanged under this Agreement shall be treated as Confidential Information under
the SDA, subject to the exceptions therein. Sections 7.7 and 7.8 of the SDA are incorporated herein by reference, mutatis mutandis. Each Party hereby acknowledges and agrees that the remedy at Law for any breach of its confidentiality
obligations under the SDA with respect to the Confidential Information exchanged under this Agreement would be inadequate and that the Disclosing Party shall be entitled to injunctive relief, without the requirement of posting any bond or other
security, in addition to any other remedy it may have upon breach of any provision of this Agreement or any applicable provision of the SDA. 

ARTICLE VII 
 REPRESENTATIONS,
WARRANTIES & COVENANTS 
 7.1 Warranties by both Parties. Each Party represents, warrants and covenants to the other Party
that: 
 7.1.1 it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, to
conduct its business as currently conducted and to enter into this Agreement, and to consummate the transactions contemplated by this Agreement; 

7.1.2 neither the execution, delivery nor performance of this Agreement by such Party violates or conflicts with, or will violate or conflict
with, any provision of such Party’s organizational or governing documents or instruments, nor are there any inconsistencies, to the best of such Party’s knowledge, between the terms of this Agreement and any of such Party’s
obligations to third parties or under Applicable Law, which bind or encumber it or its property; 

  
 26 

 7.1.3 the execution, delivery and performance of this Agreement has been duly authorized by such
Party’s appropriate authorizing authority or other applicable governing body and by any other necessary corporate or other legal actions of such Party, and this Agreement constitutes the valid and binding obligation of such Party, enforceable
in accordance with its terms, except as such enforceability may be limited by general principles of equity or bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally; 

7.1.4 its performance of services under this Agreement will comply with all Applicable Laws; and 

7.1.5 there are no actions, suits, claims or proceedings (pending or threatened) against, by, or affecting such Party in any court or before
any arbitrator or governmental agency or authority that may have a material adverse effect on such Party’s assets, its financial condition, the operation of its business or its ability to perform its obligations under this Agreement. 

7.2 Additional Warranties by Emergent. Emergent represents, warrants and covenants to Aptevo as follows: 

7.2.1 with respect to each Vial of Product that is Delivered, the Manufacturing Emergent performs hereunder will be performed in accordance
with the Quality Agreement, the Specifications and cGMPs; 
 7.2.2 as of the Delivery of each Vial, such Vial is Conforming Product. 

7.2.3 no individual who has been debarred by the FDA (pursuant to 21 U.S.C. Section 335a) or local regulatory or federal agency from
providing services in any capacity to a person that has an approved or pending drug product application (a “Debarred Individual”), or an individual or entity known to Emergent to be an employer, employee, partner or Affiliate of a
Debarred Individual, will be in any manner employed or used by Emergent in the Manufacture of the Products or any related activities; 

7.2.4 neither Emergent, nor any Affiliate of Emergent that may be involved in the Manufacturing of the Products, is a corporation,
partnership, association or other legal entity that has been debarred by the FDA (pursuant to 21 U.S.C. Section 335a) or local regulatory or federal agency from submitting or assisting in the submission of any abbreviated drug application (a
“Debarred Entity”); 
 7.2.5 as of the Delivery of each Vial of Product, Emergent has good and marketable title to such
Products, and as of Delivery all Products so Delivered are free from all liens, charges, encumbrances and security interests, other than (a) licenses of Intellectual Property pursuant to this Agreement and (b) any liens that are effected
by operation of law and that do not adversely affect Aptevo’s ability to own, use or sell the applicable Product (for clarity, this Section 7.2.5 shall not be interpreted to include any representation, warranty, or covenant
regarding the non-infringement, non-misappropriation or non-violation of any Intellectual Property rights of any third party); 

  
 27 

 7.2.6 any changes made after the Effective Time to the Manufacturing process used by Emergent to
Manufacture the Products (other than Product-Specific Manufacturing Improvements proposed and approved by Aptevo) do not and will not infringe, misappropriate or otherwise violate the Intellectual Property rights or any other right of any third
party; 
 7.2.7 under this Agreement, Emergent, or any Affiliate of Emergent, will satisfy the requirements of a distributor, as such term
is defined in the Good Manufacturing Process Guidelines, 2009 Edition, Version 2 (GUI-0001), as issued March 4, 2011 by Health Canada (the “Distributor”) and will act as a Distributor for Aptevo with respect to each Product
under this Agreement that is distributed in Canada and will uphold any and all requirements set forth by the GMPs under Division 2, Part C of the Food and Drug Regulations (Consolidated Regulations of Canada, Chapter 870) as applied to an entity
that does not hold the drug identification number for a product acting as a distributor for such product. 
 7.3 Additional Warranties by
Aptevo. Aptevo represents, warrants and covenants to Emergent as follows: 
 7.3.1 Aptevo’s storage, labeling, distribution, use,
and sale of Products and 3PL-Only Products complies and will comply with all Applicable Law; 
 7.3.2 all necessary import and export
licenses are in place or will be in place at the time of import or export (as applicable), and the import, export, distribution and sale of Products or 3PL-Only Products materially comply with all Applicable Law; 

7.3.3 all necessary approvals of the FDA or any other Governmental Authority, whether federal, state, local or foreign, for the purpose for
which the Products and 3PL-Only Products are intended to be distributed or sold, are in place or will be in place at the time of distribution or sale; and 

7.3.4 Aptevo is not aware of any action or proceeding by any Regulatory Authority threatened against Aptevo relating to safety or efficacy of
any of the Products or 3PL-Only Products, other than periodic discourse with the FDA or other Regulatory Authority related thereto. 
 7.4
Disclaimer of Warranties. EXCEPT FOR THE WARRANTIES SET FORTH IN SECTIONS 7.1, 7.2 AND 7.3, OR AS EXPRESSLY SET FORTH IN THE SDA OR ANY ANCILLARY AGREEMENT, EMERGENT HEREBY DISCLAIMS ALL CONDITIONS, WARRANTIES AND
STATEMENTS IN RESPECT OF THE MATERIALS, THE PRODUCTS AND SERVICES PROVIDED HEREUNDER, WHETHER EXPRESS OR IMPLIED, CUSTOM OF THE TRADE OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ANY SUCH CONDITION, WARRANTY OR STATEMENT RELATING TO MERCHANTABILITY,
NONINFRINGEMENT, FITNESS FOR A PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS. 

  
 28 

 ARTICLE VIII 

INDEMNIFICATION AND LIMITATION ON LIABILITY 

8.1 Indemnification by Emergent. Subject to the limitations set forth in Section 8.4 below, Emergent shall indemnify,
defend and hold harmless Aptevo, its Affiliates and their respective directors, officers, employees, and agents, from and against any and all Liabilities arising out of Third-Party Claims to the extent as a result of (a) the failure of Emergent
to perform the Manufacturing in compliance with cGMP or the Specifications, (b) the fraud, gross negligence or willful misconduct of Emergent, its directors, officers, employees or agents in the performance of its obligations under this
Agreement, (c) the recall, product withdrawal or other field correction action of any Product by the FDA, other Governmental Authority or otherwise, to the extent caused by Emergent’s Delivery of Product that, as of such Delivery, does not
meet Specifications, (d) any changes made after the Effective Time to the Manufacturing process used by Emergent to Manufacture the Products (except to the extent resulting solely from a Product-Specific Manufacturing Improvement proposed and
approved by Aptevo) or (e) any alleged or actual infringement or misappropriation of Third Party Intellectual Property rights to the extent resulting from Emergent’s use of any Emergent information, data or property in the performance of
this Agreement or resulting from any Facility Improvements and Platform Manufacturing Improvements. 
 8.2 Indemnification by Aptevo.
Aptevo will indemnify, defend, and hold harmless Emergent, its Affiliates and their respective directors, officers, employees, and agents, from and against any and all Liabilities arising out of Third-Party Claims to the extent as a result of
(a) the promotion, distribution, marketing, sale or use of any Product or 3PL-Only Product by Aptevo or any third party, including any product liability claim of a third party (except to the extent such claim is subject to Emergent’s
indemnification obligations under Section 8.1 above), (b) the fraud, gross negligence or willful misconduct of Aptevo, its directors, officers, employees or agents in the performance of its obligations or exercise of its rights
under this Agreement, (c) any alleged or actual infringement or misappropriation of third party Intellectual Property rights in the Products or 3PL-Only Products or any portion thereof (except to the extent such claim is subject to
Emergent’s indemnification obligations under Section 8.1 above), or resulting from use of any Aptevo information, data or property in the performance of this Agreement, including without limitation the labeling specifications provided to
Emergent by Aptevo, (d) the recall, product withdrawal or other field correction action of any Product by the FDA, other Governmental Authority or otherwise (other than recalls for which Emergent is obligated to indemnify Aptevo pursuant to
Section 8.1(c)) or (e) the breach by Aptevo of its representations, warranties, obligations or covenants hereunder (except for a breach of payment obligations). 

8.3 Conditions. Promptly after a Party (the “Indemnified Party”) obtains knowledge of the existence or commencement of
any claim or proceeding with respect to which the Indemnified Party is entitled to indemnification under Section 8.1 or 8.2, such Indemnified Party will notify the other Party (the “Indemnifying Party”) of such
claim or proceeding in writing; 

  
 29 

 
provided, however, that any failure to give such notice will not waive any rights of the Indemnified Party except to the extent that the rights of the Indemnifying Party are actually prejudiced
thereby. The Indemnifying Party will assume the defense and settlement of such claim or proceeding with counsel reasonably satisfactory to the Indemnified Party at the Indemnifying Party’s sole risk and expense; provided, however, that the
Indemnified Party (i) will reasonably cooperate with the Indemnifying Party in the defense and settlement of such claim or proceeding, and (ii) may not settle any such claim or proceeding without the Indemnifying Party’s written
consent (not to be unreasonably withheld or delayed). The Indemnifying Party may not settle any such claim or proceeding without the Indemnified Party’s written consent, unless such settlement (x) includes a release of all covered claims
or proceedings pending against the Indemnified Party; (y) contains no admission of liability or wrongdoing by the Indemnified Party; and (z) imposes no obligations upon the Indemnified Party. 

8.4 Limitation on Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, THE SDA, THE TSA OR ANY OTHER ANCILLARY
AGREEMENT: 
 8.4.1 EXCEPT FOR BREACHES OF ARTICLE VI, SECTIONS 2.6.1, 2.6.2, 2.6.3 OR 12.4.2, TO THE
MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY PARTY CLAIMING THROUGH OR UNDER SUCH OTHER PARTY FOR ANY LOST PROFITS OR REVENUES, OR FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE
OR CONSEQUENTIAL DAMAGES HOWEVER CAUSED, WHETHER IN AN ACTION IN CONTRACT, TORT (INCLUDING STRICT LIABILITY), BASED ON A WARRANTY, OR OTHERWISE, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF THE FIRST PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES; 
 8.4.2 EMERGENT SHALL BE ENTITLED TO SEEK LOST PROFITS, OR INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL
DAMAGES, AGAINST APTEVO, ANY MEMBER OF THE APTEVO GROUP, ANY ACQUIRING PARTY OR ANY AFFILIATE OF THE FOREGOING ARISING OUT OF OR IN CONNECTION WITH ANY BREACH OF ARTICLE VI, SECTIONS 2.6.2, 2.6.3 OR 12.4.2, DIRECTLY OR
INDIRECTLY, BY APTEVO OR ANY OF THE FOREGOING. 
 8.4.3 EXCEPT FOR APTEVO’S INDEMNITY OBLIGATIONS UNDER SECTION 8.2 AND FOR
EITHER PARTY’S BREACH OF ARTICLE VI, SECTIONS 2.6.1, 2.6.2, 2.6.3 OR 12.4.2, EACH PARTY’S LIABILITY FOR ALL CLAIMS ARISING UNDER THIS AGREEMENT SHALL NOT EXCEED THE AMOUNT PAID BY APTEVO TO EMERGENT UNDER
THIS AGREEMENT DURING THE ONE YEAR PRECEDING THE EVENT THAT GAVE RISE TO SUCH CLAIM; PROVIDED, HOWEVER, THAT THE FOREGOING SHALL NOT LIMIT APTEVO’S PAYMENT OBLIGATIONS FOR PURCHASE OF PRODUCT AND SERVICES OR OTHER FEES DUE HEREUNDER, INCLUDING
WITHOUT LIMITATION ANY AMOUNTS PAYABLE IN CONNECTION WITH MINIMUM ANNUAL ORDER OBLIGATIONS PURSUANT TO SECTION 3.1.5; AND 

  
 30 

 8.4.4 EMERGENT’S LIABILITY FOR THE REPLACEMENT OF OR THE COST OR VALUE OF ANY MATERIALS
(EXCLUDING ACTIVE PHARMACEUTICAL INGREDIENTS) OR PRODUCTION EQUIPMENT SUPPLIED TO EMERGENT HEREUNDER BY APTEVO (IF ANY), INCLUDING BUT NOT LIMITED TO ANY MATERIALS (EXCLUDING ACTIVE PHARMACEUTICAL INGREDIENTS) OR SUCH PRODUCTION EQUIPMENT LOST OR
DAMAGED, SHALL BE LIMITED TO THE ACTUAL VALUE THEREOF, BUT IN ANY EVENT SHALL NOT EXCEED EMERGENT’S INSURANCE COVERAGE FOR PROPERTY OF OTHERS AND ANY RELATED LOSS OR DAMAGE. APTEVO WILL BE RESPONSIBLE FOR PROVIDING THE VALUE OF ANY CLAIMED LOSS
TO EMERGENT’S INSURANCE CARRIER FOR LOSSES COVERED BY EMERGENT’S INSURANCE POLICY. 
 8.5 Interaction with the SDA and other
Ancillary Agreements. Notwithstanding anything to the contrary in the SDA, in no event may any claim, including any Dispute, under or with respect to the subject matter of this Agreement be the basis of an indemnification claim under Article IV
of the SDA or under any other Ancillary Agreement. 
 ARTICLE IX 

TERM AND TERMINATION 
 9.1
Term. Unless terminated in accordance with the provisions of Section 9.2, the term of this Agreement shall commence on the date hereof and continue for a period of ten (10) years. 

9.2 Termination. This Agreement may be terminated: 

9.2.1 by either Party immediately, in the event of an Insolvency/Bankruptcy Event with respect to the other Party; 

9.2.2 by Emergent immediately, or at Emergent’s discretion, suspended immediately, upon written notice to Aptevo if Aptevo fails to pay
Emergent in full any undisputed amount due and payable in connection with this Agreement within forty-five (45) days after receipt of written notice from Emergent of such failure; 

9.2.3 by the non-breaching Party immediately, if the other Party has materially breached this Agreement and fails to cure such breach
(a) within thirty (30) days after receipt of written notice thereof or (b) if such breach cannot be cured within such thirty (30) day period, such period of time as the breaching Party is diligently making efforts to cure such
breach, but in no event more than ninety (90) days after receiving notice of such breach from the non-breaching Party; 
 9.2.4 by
Aptevo, in its entirety, by providing not less than twenty-four (24) months’ written notice; 

  
 31 

 9.2.5 by Emergent, in its entirety, by providing not less than thirty-six (36) months’
written notice; 
 9.2.6 by Aptevo, immediately upon written notice to Emergent in the event of a Manufacturing Failure; or 

9.2.7 by Aptevo, solely with respect to all 3PL Services, by providing not less than six (6) months’ written notice. 

Notwithstanding the above, in no event shall notice or intention to terminate be deemed to waive any rights to damages or any other remedy which the Party
giving notice of failure to pay or breach under Sections 9.2.2 or 9.2.3 may have as a consequence of such failure or breach. 

9.3 Outstanding Obligations. Termination or expiration of this Agreement, for whatever reason, shall not affect the obligation of
either Party to make any payments for which it is liable prior to or upon such termination. Upon any termination of this Agreement, Aptevo shall be responsible for any Binding Purchase Orders (although Emergent shall have the right, in its
discretion, to cancel any such Purchase Order) and will purchase from Emergent, at a price equal to Emergent’s cost therefor, any Materials purchased for the Products (based on forecasts or otherwise) which Emergent has reasonably purchased or
ordered which cannot be canceled. Upon receipt of such payment, Emergent shall immediately deliver such Materials to Aptevo EXW (such Materials’ locations). Section 4.4(a) of the PLA is hereby incorporated by reference. 

9.4 Manufacturing Failure; CMO Appointment. If (i) a Manufacturing Failure occurs, and if Aptevo obtains the right, under
Section 2.1(b) of the PLA, to exercise the right to have a Product manufactured by a CMO (as such term is defined in the PLA), or (ii) Emergent approves of a CMO in its sole and absolute discretion pursuant to
Section 2.1(b) of the PLA (each, a “Triggering Event”), Emergent shall, itself or through the relevant member of the Emergent Group: 

9.4.1 Technology Transfer. Provide reasonable assistance in the transfer of the Manufacturing Technology (as such term is defined in
the PLA) and the Included Manufacturing Improvements to such CMO as follows: (i) Emergent will, without charge to Aptevo or the CMO, provide to such CMO the documentation of the Manufacturing Technology and the Included Manufacturing
Improvements, in hard copy or electronic form, that is in Emergent’s possession and control; (ii) Emergent will provide up to seven hundred fifty (750) FTE-hours of support without charge to Aptevo or the CMO to train such CMO in
using such Manufacturing Technology and Included Manufacturing Improvements; and (iii) if such CMO needs reasonable additional assistance to use the Manufacturing Technology and Included Manufacturing Improvements, beyond the seven hundred
fifty (750) FTE-hours set forth in the foregoing clause (ii), then Emergent will provide such reasonably requested support for up to three (3) years after the beginning of the technology transfer process and Aptevo will reimburse Emergent
for such additional support at Emergent’s then-standard rate. 

  
 32 

 9.4.2 Manufacturing License. Subject to the terms and conditions of this Agreement, grant
to Aptevo a royalty-free, worldwide, non-transferable (except as provided in this Section 9.4.2 and for certain assignments as provided in Section 12.4) license, under the Included Manufacturing Improvements in the form in
which such Included Manufacturing Improvements exist at the time of the Triggering Event, to make, have made, use, sell, offer to sell, import and otherwise commercialize the Products, solely within the Field, provided that Aptevo may only exercise
(and the other members of the Aptevo Group may only exercise) the rights to make and have made the Products through such CMO pursuant to and in accordance with the PLA. Sections 2.6.3, 2.6.5 and 2.6.6 of this Agreement shall
apply to Aptevo with respect to such license. Such license is subject to Aptevo’s compliance with the terms of this Section 9.4.2 and, as applicable, Section 12.4 and shall terminate (a) upon the termination of the
PLA for any reason or (b) if Aptevo breaches any term of any of Sections 2.6.3, 2.6.5, 2.6.6, this 9.4.2 or 12.4 and (i) fails to cure such breach within ninety (90) days after receipt of written
notice of such breach from Emergent or (ii) if such breach is incapable of cure, as determined by Emergent in Emergent’s reasonable discretion. 

ARTICLE X 
 INSURANCE 

10.1 Product Liability Insurance. Aptevo and Emergent shall each, at its own expense, maintain product liability insurance coverage,
through the term of this Agreement and for a period of six (6) years thereafter, of at least ten million dollars ($10,000,000). Aptevo and Emergent will provide a certificate of insurance to the other upon request. Emergent shall be covered as
an additional insured on Aptevo’s product liability policy. If such product liability insurance is underwritten on a claims made basis, Aptevo and Emergent agree that any change of the fronting insurance carriers may require the purchase of
prior acts coverage to ensure that coverage will be continuous throughout the term of this Agreement and for a period of six (6) years thereafter. 

10.2 Insurance; Liability to Third Persons. Emergent and Aptevo, each at their own expense, shall obtain and thereafter maintain during
the term of this Agreement: 
 10.2.1 workers’ compensation as required by all applicable laws and Employer’s Liability insurance
with a policy limit of not less than one million dollars ($1,000,000); and 
 10.2.2 A combination of commercial general liability insurance
and excess or umbrella insurance including contractual liability with combined minimum limits of ten million dollars ($10,000,000) for each occurrence and in the aggregate. 

Each Party shall immediately give the other or its representative notice of any suit or action filed, or prompt notice of any claim made, against them arising
out of the performance of this Agreement. 

  
 33 

 ARTICLE XI 

DISPUTE RESOLUTION 
 11.1
Resolution Process. Notwithstanding anything to the contrary in the SDA, any Dispute (as defined below) shall be resolved exclusively in accordance with the following provisions of this ARTICLE XI: 

11.1.1 Disputes. Any controversy or claim arising after the Effective Time and arising out of or relating to this Agreement, or the
breach hereof, other than an inability to reach agreement under Section 3.16.3 (a “Dispute”), shall be resolved: (a) first, by negotiation by the Project Managers, and then (if there remains a Dispute) negotiation
by and among the members of the Joint Steering Committee, with the possibility of mediation as provided in Section 11.1.2; and (b) then, if negotiation and mediation fail, by binding arbitration as provided in
Section 11.2. Each Party agrees on behalf of itself and each of its Subsidiaries that the procedures set forth in this ARTICLE XI shall be the exclusive means for resolution of any Dispute. The initiation of mediation or
arbitration hereunder will toll the applicable statute of limitations for the duration of any such proceedings. 
 11.1.2 Negotiation and
Mediation. If either Party serves written notice of a Dispute upon the other Party (a “Dispute Notice”), the Parties will first attempt to resolve such Dispute by direct discussions and negotiation (including as set forth in
Section 11.1.1 above). If the Parties agree, the Parties may also attempt to resolve the Dispute by a mediation administered by the International Institute for Conflict Prevention & Resolution (“CPR”) under its
Mediation Procedure. 
 11.2 Arbitration. 

11.2.1 If a Dispute is not resolved within forty-five (45) days (or later if mutually agreed by the Parties) after the service of a
Dispute Notice, either Party shall have the right to commence arbitration. The arbitration shall be administered by the CPR pursuant to its Arbitration Rules and Procedures. References herein to any arbitration rules or procedures mean such rules or
procedures as amended from time to time, including any successor rules or procedures, and references herein to the CPR include any successor thereto. The arbitration shall be before three (3) arbitrators. Each Party shall designate one
arbitrator in accordance with the “screened” appointment procedure provided in Rule 5.4 of the CPR Rules. The two Party-appointed arbitrators will select the third, who will serve as the panel’s chair or president. This arbitration
provision, and the arbitration itself, shall be governed by the Laws of the State of Delaware and the Federal Arbitration Act, 9 U.S.C. §§ 1-16. 

11.2.2 Consistent with the expedited nature of arbitration, each Party will, upon the written request of the other Party, promptly provide the
other with copies of documents on which the producing Party may rely in support of or in opposition to any claim or defense. At the request of a Party, the arbitrators shall have the discretion to order examination by deposition of witnesses to the
extent the arbitrator deems such additional discovery relevant and appropriate. Depositions shall be limited to a maximum of five (5) per Party and shall be held within forty-five (45)

  
 34 

 
days of the grant of a request. Additional depositions may be scheduled only with the permission of the arbitrators, and for good cause shown. Each deposition shall be limited to a maximum of one
day’s duration. All objections are reserved for the arbitration hearing except for objections based on privilege and proprietary or confidential information. The Parties shall not utilize any other discovery mechanisms, including international
processes and U.S. federal statutes, to obtain additional evidence for use in the arbitration. Any dispute regarding discovery, or the relevance or scope thereof, shall be determined by the arbitrators, which determination shall be conclusive. All
discovery shall be completed within 120 days following the appointment of the arbitrators. All costs and fees relating to the retrieval, review and production of electronic discovery shall be paid by the Party requesting such discovery. 

11.2.3 The panel of arbitrators shall have no right, power or authority, under the CPR Rules for Non-Administered Arbitration or otherwise, to
(i) award non-monetary or equitable relief of any sort (except as set forth in Section 2.6.3, ARTICLE VI, and except in the event of a breach of Section 12.4.2 or as necessary to otherwise enforce
Section 12.4.2); (ii) relieve the Parties from their agreement hereunder to arbitrate or otherwise to amend or disregard any provision of this Agreement; (iii) limit, expand, alter, amend, modify, revoke or suspend any
condition or provision of this Agreement; or (iv) adjudicate any matters pertaining to the SDA or any Ancillary Agreement other than this Agreement. 

11.2.4 Absent fraud or manifest error, any arbitral award issued hereunder shall be final, binding and the sole and exclusive remedy to the
Parties. Either Party may seek to confirm and enforce any final award entered in arbitration, in any court of competent jurisdiction. 

11.2.5 Except as may be required by Law or any applicable rules and regulations of any stock exchange, neither a Party nor an arbitrator may
disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties. 
 11.3
Expert Resolution for Lack of Agreement in Section 3.16.3. If the Parties are unable to reach agreement within thirty (30) days of beginning discussions under Section 3.16.3, the disagreement shall be resolved
pursuant to this Section 11.3. 
 11.3.1 Any matter under this Section 11.3 shall be referred to a person suitably
qualified to determine such matter who shall be jointly nominated and approved by the Parties (the “Expert”). The Expert will act as an expert, not as an arbitrator. Any fee due the Expert shall be shared by the Parties. The
Expert’s terms of appointment shall include: (i) a requirement that the Expert act fairly; (ii) unless otherwise agreed by the Parties, a requirement that the Expert hold adequate professional indemnity insurance both then and for at
least the period of statutory limitation following the date of the Expert’s determination; (iii) confidentiality obligations reasonably acceptable to the Parties; and (iv) a commitment by the Parties to supply to the Expert all such
assistance, documents and information as the Expert may reasonably require for the purpose of his or her determination. 

  
 35 

 11.3.2 Within fifteen (15) days after the designation of the Expert pursuant to
Section 11.3.1, the Parties shall each simultaneously submit to the Expert and one another a written statement of their respective positions on the disagreement. Each Party shall have five (5) days from receipt of the other
Party’s submission to submit to the Expert and the other Party a written response thereto, which shall include any specific financial or back-up information in support thereof. The Expert shall have the right to meet with the Parties,
either alone or together, as necessary to make a determination. 
 11.3.3 No later than thirty (30) days after the designation of the
Expert, the Parties shall each submit a final proposal to the Expert, who shall select one of such proposals based on the Expert’s opinion as to the overall fairness and reasonableness of such proposal in light of the totality of the
circumstances. The Expert shall provide the Parties with a written statement setting forth the basis of the determination. The decision of the Expert shall be final and conclusive, absent manifest error on all such matters. 

11.4 Interim Relief. At any time during the resolution of a dispute between the Parties, either Party has the right to apply to any
court of competent jurisdiction for interim relief, including pre-arbitration attachments or injunctions, necessary to preserve the Parties’ rights or to maintain the Parties’ relative positions until such time as the arbitration award is
rendered or the dispute is otherwise resolved. 
 11.5 Expenses. Each Party shall bear its own costs, expenses and attorneys’
fees in pursuit and resolution of any dispute; provided, however, that, in the event of any arbitration with respect to any dispute pursuant to Section 11.1 in which the arbitrator issues an arbitral award in an amount that is within ten
percent (10%) of the amount of the most recent bona fide written settlement offer submitted by a Party and rejected by a Party in connection with such dispute, then the Party that rejected such settlement offer shall bear both Parties’
costs, expenses and attorneys’ fees incurred in connection with such arbitration (including the fees and expenses of any arbitrator). 

ARTICLE XII 
 MISCELLANEOUS 

12.1 Provisions from the SDA. The Parties agree and acknowledge that this Agreement is an Ancillary Agreement and, therefore, that
certain provisions of the SDA apply hereto, provided, however, that if there is any conflict between the terms of this Agreement and the terms of the SDA, the terms of this Agreement apply with respect to the subject matter hereof. Sections 11.1
(Counterparts; Entire Agreement; Corporate Power), 11.2 (Governing Law), 11.6 (Severability), 11.10 (Headings), 11.11 (Survival of Covenants), 11.12 (Waivers of Default), 11.14 (Amendments), 11.15 (Interpretation) and 11.16 (No Set Off) of the SDA
are incorporated herein by reference, mutatis mutandis. 
 12.2 Notices. All notices, requests, claims, demands or other
communications under this Agreement shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by

  
 36 

 
facsimile or electronic transmission with receipt confirmed (followed by delivery of an original via overnight courier service) or by registered or certified mail (postage prepaid, return receipt
requested) to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance with this Section 12.2): 

If to Emergent, to: 
 [●]

 with a copy to: 
 [●]

 If to Aptevo to: 

[●] 
 with a copy to: 

[●] 
 Any Party may, by
notice to the other Party, change the address and contact person to which any such notices are to be given. 
 12.3 Force Majeure. If
either Party fails to fulfill its obligations hereunder (other than an obligation for the payment of money), when such failure is due to an act of God, or other circumstances beyond its reasonable control (to the extent such Party could not have
mitigated the effects of such events using reasonable efforts), including but not limited to unanticipated Manufacturing Facility shutdown, supplier delays or failures, equipment failure, fire, flood, civil commotion, riot, war (declared and
undeclared), revolution, action by government including delays in obtaining governmental approvals or embargoes, then said failure shall be excused for the duration of such event and for such a time thereafter as is reasonable to enable the Parties
to resume performance under this Agreement. Any failure of Emergent in performing its obligations hereunder due to Aptevo’s failure to provide to Emergent any information, assistance or material necessary for Emergent to perform its activities
under this Agreement shall also so excuse Emergent’s failure. 
 12.4 Assignability. 

12.4.1 This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.
Except as otherwise provided for in this Agreement, this Agreement shall not be assignable by either Party, in whole or in part, without the express written consent of the other Party, and any attempt to assign any rights or obligations arising
under this Agreement without such consent shall be void. Notwithstanding the foregoing, no such consent shall be required for (i) the assignment of all of Aptevo’s rights and obligations under this Agreement to an acquirer of all or
substantially all of the assets of the 

  
 37 

 
Aptevo Group relating to all the Products, (ii) the assignment of all of Emergent’s rights and obligations under this Agreement to an acquirer of all or substantially all of the assets
of Emergent relating to the Manufacturing Technology or (iii) the licensing, assignment or otherwise transferring of any Aptevo Intellectual Property, subject to the license granted to Emergent herein. 

12.4.2 If Aptevo or a member of the Aptevo Group (in each case, except to the extent otherwise expressly permitted by this Agreement or any
other Ancillary Agreement), or any successor or assignee of Aptevo, or an Acquiring Entity operates a Competing Program, (i) such Person and its Affiliates shall establish and enforce internal processes, policies, procedures and systems to
strictly segregate information relating to any Competing Program from the Manufacturing Technology and the Included Manufacturing Improvements; (ii) such Person and its Affiliates shall not use, directly or indirectly, any Manufacturing
Technology, Included Manufacturing Improvements or any Confidential Information of Emergent in such Competing Program (except that a CMO is permitted to use the Manufacturing Technology and the Included Manufacturing Improvements solely to
manufacture the Products on behalf of Aptevo or its successor or assignee, as applicable, solely in accordance with the terms of this Agreement and the PLA); (iii) no personnel who had access to the Manufacturing Technology or Included
Manufacturing Improvements at any time may conduct any activities under such Competing Program (except that a CMO is permitted to use the Manufacturing Technology and the Included Manufacturing Improvements solely to manufacture the Products on
behalf of Aptevo or its successor or assignee, as applicable, solely in accordance with the terms of this Agreement and the PLA); and (iv) Emergent may abstain from sharing with such Person and its Affiliates any Confidential Information
related to the Manufacturing Technology or the Included Manufacturing Improvements, in its sole discretion. Notwithstanding anything else to the contrary in the Agreement, following an assignment of this Agreement by a Party in accordance with such
Party’s right to assign this Agreement under Section 12.4.1(i) or (ii), as applicable, the assigning Party may request from the non-assigning Party that the assigning Party be released from liability with regard to the
actions of such assignee under this Agreement following such assignment, which release shall not be unreasonably withheld or delayed. 

12.4.3 Nothing herein shall prevent Emergent or any member of the Emergent Group from, subject to the licenses granted to Aptevo herein,
licensing, assigning or otherwise transferring any right, title or interest in or to any Licensed IP or Included Manufacturing Improvements. 

12.4.4 To the extent either Party assigns the Intellectual Property underlying any license granted under this Agreement, such Party shall
assign the applicable portions of this Agreement to such assignee. 
 12.4.5 Notwithstanding anything to the contrary contained herein in
the SDA or in any other Ancillary Agreement, any attempt by Aptevo to assign any rights or obligations arising under this Agreement, the CDA or the PLA shall be void unless Aptevo concurrently assigns this Agreement, the CDA and the PLA (to the
extent such agreements have not terminated or expired) to the same assignee, and (b) the applicable assignment, transfer 

  
 38 

 
(including by operation of law) or change of control of Aptevo shall be void unless the same person or entity is, as of any relevant time, “Aptevo” under this Agreement and
“Aptevo” under the CDA and PLA. 
 12.4.6 The assigning Party shall remain bound by all obligations with respect to the other
Party’s Confidential Information under this Agreement. The non-assigning Party may disclose the assigning Party’s Confidential Information to the assignee as necessary for the non-assigning Party’s performance of its obligations and
exercise of its rights under this Agreement. 
 12.5 Independent Contractors. It is expressly agreed that Emergent and Aptevo shall
be independent contractors and that the relationship between Emergent and Aptevo shall not constitute a partnership, joint venture or agency. Neither Emergent nor Aptevo shall have the authority to make any statements, representations, or
commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 

12.6 Bankruptcy. All rights and licenses granted under or pursuant to any Section of this Agreement are rights to “intellectual
property” (as defined in Section 101(35A) of Title 11 of the United States Code, as amended (the “Bankruptcy Code”)). Each Party shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code
with respect to such rights and licenses. 
 12.7 Survival. All representations, warranties, covenants and agreements made herein and
which by their express terms or by implication are to be performed after the execution and or termination hereof, or are prospective in nature, shall survive such execution or termination, as the case may be, including Sections 2.6.3,
2.6.5, 2.6.6, 3.7, 3.9, 3.17, 3.18, 3.20, 3.21, 6.1, 7.4, ARTICLE VIII, Section 9.3, Section 9.4 (solely to the extent a Triggering Event had
occurred prior to the expiration or termination of this Agreement or if this Agreement is terminated pursuant to Section 9.2.5), ARTICLE X, Sections 11.1, 11.2, 11.4, 11.5, 12.1, 12.2,
12.3, 12.4, 12.5, 12.7, 12.8 and 12.9. 
 12.8 Further Assurances. Each Party covenants and
agrees that, without any additional consideration, it shall execute and deliver any further legal instruments and perform any acts that are or may become necessary to effectuate this Agreement. For clarity, nothing in this Section 12.8
shall be construed as an obligation on the part of either Party to perform any services. 
 12.9 Quality Agreement. The Quality
Agreement shall, together with this Agreement, apply to the provision of any service contemplated under this Agreement solely to the extent such service relates to quality assurance matters and is within the subject matter of the Quality Agreement.
In the event of any conflict or inconsistency between the Quality Agreement and this Agreement solely with respect to quality assurance matters, the Quality Agreement shall control. In the event of any other conflict or inconsistency (including, for
the avoidance of doubt, with respect to the respective remedies of the parties with respect to any service contemplated under this Agreement), this Agreement shall control. 

  
 39 

 [Signature Page Follows] 

  
 40 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed on the date first
written above by their duly authorized representatives. 
  

			
	EMERGENT BIOSOLUTIONS INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	APTEVO THERAPEUTICS INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 [Signature Page to Manufacturing Services Agreement] 

 LIST OF SCHEDULES: 
  

			
	Schedule A.	  	Pricing
		
	Schedule B.	  	Order Minimums
		
	Schedule C.	  	Quality Agreement
		
	Schedule D.	  	IXINITY Packaging Services
		
	Schedule E.	  	3PL Services

 Schedule A 

Pricing 

 Schedule B 

Order Minimums 

 Schedule C 

Quality Agreement 

 Schedule D 

IXINITY Packaging Services 

 Schedule E 

3PL ServicesEX-10.5

 Exhibit 10.5 

CANADIAN DISTRIBUTOR AGREEMENT 

BY AND BETWEEN 
 EMERGENT
BIOSOLUTIONS INC. 
 AND 

APTEVO THERAPEUTICS INC. 
 DATED
AS OF [●], 2016 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE I Definitions
	  	 	1	  
		
	 ARTICLE II Appointment and Term
	  	 	2	  
			
	 2.1
	 	 Appointment.
	  	 	2	  
	 2.2
	 	 License to Distributor.
	  	 	2	  
	 2.3
	 	 Initial Term and Renewal.
	  	 	3	  
	 2.4
	 	 Products.
	  	 	3	  
	 2.5
	 	 Delegation
	  	 	3	  
		
	 ARTICLE III Payment
	  	 	3	  
			
	 3.1
	 	 Payment Terms.
	  	 	3	  
	 3.2
	 	 Payment without Deductions.
	  	 	3	  
		
	 ARTICLE IV Distributor’s Obligations
	  	 	3	  
		
	 ARTICLE V Aptevo’s Obligations
	  	 	5	  
		
	 ARTICLE VI Confidentiality
	  	 	6	  
		
	 ARTICLE VII Representations & Warranties
	  	 	6	  
			
	 7.1
	 	 Warranties by both Parties.
	  	 	6	  
	 7.2
	 	 Additional Warranties by Distributor
	  	 	7	  
	 7.3
	 	 Additional Warranties by Aptevo.
	  	 	7	  
	 7.4
	 	 Disclaimer of Warranties.
	  	 	8	  
		
	 ARTICLE VIII Indemnification and Limitation of Liability
	  	 	8	  
			
	 8.1
	 	 Indemnification by Distributor.
	  	 	8	  
	 8.2
	 	 Indemnification by Aptevo.
	  	 	8	  
	 8.3
	 	 Conditions.
	  	 	8	  
	 8.4
	 	 Limitation on Liability.
	  	 	9	  
	 8.5
	 	 Interaction with the SDA and other Ancillary Agreements.
	  	 	9	  
		
	 ARTICLE IX Insurance
	  	 	9	  
			
	 9.1
	 	 Distributor Insurance.
	  	 	9	  
	 9.2
	 	 Aptevo Insurance.
	  	 	10	  
		
	 ARTICLE X Termination
	  	 	10	  
			
	 10.1
	 	 By Either Party.
	  	 	10	  
	 10.2
	 	 By Aptevo.
	  	 	11	  
	 10.3
	 	 By Emergent.
	  	 	11	  
		
	 ARTICLE XI Consequences of Termination
	  	 	11	  
			
	 11.1
	 	 Return of Materials
	  	 	11	  
	 11.2
	 	 No Further Representations.
	  	 	11	  
	 11.3
	 	 Rights Terminated.
	  	 	12	  
	 11.4
	 	 Outstanding Payments.
	  	 	12	  
	 11.5
	 	 Survival of Provisions.
	  	 	12	  

  
 i 

							
	 ARTICLE XII Dispute Resolution
	  	 	12	  
			
	 12.1
	 	 Resolution Process.
	  	 	12	  
	 12.2
	 	 Arbitration.
	  	 	12	  
	 12.3
	 	 Interim Relief.
	  	 	13	  
	 12.4
	 	 Expenses.
	  	 	13	  
		
	 ARTICLE XIII Miscellaneous
	  	 	14	  
			
	 13.1
	 	 Provisions from the SDA.
	  	 	14	  
	 13.2
	 	 Notice.
	  	 	14	  
	 13.3
	 	 Assignability.
	  	 	15	  
	 13.4
	 	 No Agency.
	  	 	15	  
	 13.5
	 	 Quality Agreement.
	  	 	15	  

  
 ii 

 This CANADIAN DISTRIBUTOR AGREEMENT dated as of [●], 2016 (this
“Agreement”), is made and entered into by and between Emergent BioSolutions Inc., a Delaware corporation (“Emergent” or “Distributor”) (for whom its designee, Cangene Corporation, a corporation
organized under the laws of Canada and a member of the Emergent Group, assumes all rights and obligations under this Agreement), and Aptevo Therapeutics, Inc., a corporation organized under the laws of Delaware (“Aptevo”). Unless
otherwise defined in this Agreement, all capitalized terms used in this Agreement shall have the meaning set forth in the Separation and Distribution Agreement (“SDA”), or, if not therein, in the Transition Services Agreement
(“TSA”), or, if not therein, in the Manufacturing Services Agreement (“MSA”), or, if not therein, in the Product Licensing Agreement (the “PLA”), or, if not therein, in the Trademark License
Agreement (“TLA”), each dated as of the date hereof, by and between Emergent and Aptevo. The Parties acknowledge and agree that this Agreement is an Ancillary Agreement under the SDA. 

WHEREAS, Aptevo and Emergent have entered into the SDA, the TSA, the MSA, the TLA and the PLA; 

WHEREAS, Aptevo is a developer and manufacturer of pharmaceutical products; 

WHEREAS, Aptevo, a foreign drug identification number owner, desires to ship certain of its pharmaceutical products to destinations in the
Territory (as defined in this Agreement), subject to the terms and conditions set forth in this Agreement, and therefore wishes to engage a distributor as such term is defined by Applicable Law; 

WHEREAS, Distributor is, to the extent described in the MSA, capable of providing distributor services in the Territory with respect to the
Products; and 
 WHEREAS, Aptevo is prepared to appoint Distributor, and Distributor is prepared to accept the appointment, as Aptevo’s
exclusive distributor within the Territory, for the purpose of distributing certain products, subject to the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the mutual promises of the Parties, and of good and valuable consideration, it is agreed by and between the
Parties as follows: 
 ARTICLE I 

DEFINITIONS 
 In this Agreement,
the following terms shall have the following meanings: 
 “CPR” has the meaning set forth in Section 12.1.2.

 “Dispute” has the meaning set forth in Section 12.1.1. 

“Dispute Notice” has the meaning set forth in Section 12.1.2. 

“Indemnified Parties” has the meaning set forth in Section 8.3. 

“Indemnifying Party” has the meaning set forth in Section 8.3. 

  
 1 

 “Product” means each pharmaceutical product listed on the Product Schedule. 

“Product Schedule” means Schedule A as may be amended or modified from time to time by written agreement of the
Parties. 
 “QA” has the meaning set forth in Section 4.3. 

“Regulatory Approval” means any and all approvals or authorizations required from any Regulatory Authority for the commercial
exploitation of each Product in any part of the Territory. 
 “Regulatory Authority” means the applicable Governmental
Authority that has jurisdiction with respect to the distribution of the Products in the Territory. 
 “Safety Data Exchange
Agreement” or “SDEA” means the Safety Data and Exchange Agreement, by and between Emergent and Aptevo, of even date herewith, that defines the responsibilities of each Party with reference to each pharmacovigilance activity
and specifies the processes involved for the exchange of safety information, including timelines and regulatory reporting responsibilities. 

“Term” means the term of this Agreement specified in Section 2.3 below, or such shorter term if this Agreement is
terminated earlier in accordance with the terms hereof. 
 “Territory” means the country of Canada. 

“Trademarks” means each trademark and trade name, symbol or other proprietary mark affixed to or associated with a Product.

 “Distributor Fee” means the annual fee charged by Distributor to Aptevo for performing the services contemplated by this
Agreement as provided on Schedule B. 
 ARTICLE II 

APPOINTMENT AND TERM 
 2.1
Appointment. Subject to the terms and conditions of this Agreement, and subject to Distributor being the exclusive distributor of the Products in the Territory under the MSA, Aptevo appoints Distributor as the exclusive distributor for the
Products in the Territory, during the Term. Aptevo hereby grants Distributor access to all relevant Confidential Information, which Distributor may use to perform its obligations under this Agreement, and authorizes it to act for and on behalf of
Aptevo solely for purposes of Distributor’s obligations under this Agreement. 
 2.2 License to Distributor. For clarity, to the
extent not already licensed under the terms of the PLA, during the term of this Agreement, and subject to the terms and conditions of this Agreement, Aptevo grants to Distributor a non-exclusive, worldwide,
sublicenseable and royalty-free license, under any Intellectual Property owned or controlled by Aptevo or any of its Affiliates, solely to perform the services and to comply with Distributor’s obligations under the terms and conditions of this
Agreement. 

  
 2 

 2.3 Initial Term and Renewal. Subject to earlier termination in accordance with this
Agreement, the initial Term shall be for an initial period of ten (10) years commencing at the Effective Time. Unless terminated earlier in accordance herewith, this Agreement shall be renewed, for further periods of one (1) year each upon
the same terms as set out herein, unless either Party provides the other Party with at least thirty (30) days prior written notice of its intention to terminate this Agreement. 

2.4 Products. This Agreement shall apply to the Product(s) in the form in which such Product(s) are listed from time to time on the
Product Schedule attached hereto. The Product Schedule may be amended from time to time, upon mutual agreement in writing of the Parties hereto. 

2.5 Delegation. Distributor may use any of its Affiliates to fulfill any of its obligations under this Agreement. 

ARTICLE III 
 PAYMENT 

3.1 Payment Terms. Payment of the Distributor Fee shall be due from Aptevo by direct bank deposit or wire transfer pursuant to
Distributor’s written instructions within forty-five (45) days from date of invoice. Any and all late payments shall be subject to the payment of interest at the rate of 12.0% (twelve percent) per annum. In addition to any other remedies
Distributor may have in the event Aptevo does not pay an outstanding, overdue invoice for more than forty-five (45) days from the date on which Distributor provided Aptevo with written notice of such default (which notice period shall be tolled
during any bona fide dispute regarding such invoice), Distributor shall be entitled to refuse to perform any of the services contemplated by this Agreement, in its sole discretion, until all or an agreed upon portion of the aggregate amount owing
has been paid. 
 3.2 Payment without Deductions. All Distributor Fees specified hereunder are expressed as net amounts and shall be
paid by Aptevo free and clear of, and without reduction for, any withholding taxes. Aptevo shall, upon request, provide Distributor with official receipts issued by the appropriate taxing authority or such other evidence as may be reasonably
requested by Distributor to establish that such taxes have been paid. 
 ARTICLE IV 

DISTRIBUTOR’S OBLIGATIONS 

4.1 Distributor shall, at its own expense, and subject to Aptevo’s compliance with the terms of ARTICLE V, during the Term: 

4.1.1 Tracking and Receipt of Information. Track applicable Products in the Territory and serve as a point of contact for inquiries
about such Products as follows: once Aptevo submits a Shipping Order under the MSA that names Canada as the Distribution Destination, the Distributor shall thereafter track the Products delivered under such Shipping Order from the time such Products
enter the Territory until such Products are delivered to the recipient named in the Shipping Order. After the delivery of such Products, Distributor may be contacted with inquiries and other communications from entities within the Territory
pertaining 

  
 3 

 
to such Products, which communications shall be forwarded to Aptevo pursuant to Section 13.2 within five (5) Business Days upon receipt. All reporting of adverse events will be
governed by the provisions of the SDEA; 
 4.1.2 Compliance with Laws. Comply with all Laws of the Territory that apply to
Distributor with respect to this Agreement or the transactions and activities contemplated by this Agreement. Distributor shall not take any action that it knows will cause Aptevo to be in violation of any Law in the Territory; 

4.1.3 Regulatory Point of Contact. Strictly in the capacity of Aptevo’s agent, serve as the secondary point of contact and liaison
with the applicable Regulatory Authority with respect to all communications with such Regulatory Authority pertaining to the Products in the Territory, except where Distributor’s responsibilities under Applicable Law require Distributor to
liaise directly with or be the primary point of contact for the applicable Regulatory Authority. Distributor shall notify Aptevo upon being contacted by a Regulatory Authority or any other competent Governmental Authority within the Territory for
any regulatory purpose pertaining to this Agreement or the Products, including with respect to labeling or packaging, within two (2) Business Days, except for if Distributor is legally prohibited from doing so. Except for administrative
matters, Distributor shall not respond to any such Governmental Authority before consulting with Aptevo, unless under the circumstances pursuant to which such Governmental Authority contacts Distributor, Distributor is legally prohibited from giving
Aptevo advance notice. In any event, once Distributor is no longer legally prohibited from giving Aptevo advance notice, Distributor shall inform Aptevo of such contact within two (2) Business Days. For clarity, Distributor is under no
obligation to give Aptevo any regulatory, legal or other compliance advice under this Agreement and no communication from Distributor to Aptevo shall be construed as providing such advice; 

4.1.4 Regulatory Record Keeping and Information. Maintain Product regulatory records according to Distributor’s standard operating
procedures and in accordance with local Laws, such as submissions, regulatory agency correspondence and telephone contact reports; provided that Aptevo, upon the request of Distributor, provides Distributor with information and documents (in
English) that are in Aptevo’s possession relating to each Product as are required by the applicable Regulatory Authority; 
 4.1.5
Regulatory Approval Notices. Notify Aptevo as soon as reasonably possible, but in no event later than two (2) Business Days, in the event that any Regulatory Approval for a Product is revoked for any reason in the Territory; 

4.1.6 Inquiry Forwarding. Keep Aptevo informed of any inquiries from entities within the Territory by promptly forwarding such inquires
to Aptevo pursuant to Section 13.2; 
 4.1.7 Pharmacovigilance Compliance. Until one year after the expiration date of
the last Product distributed in commerce produced under the MSA, comply with the terms and conditions of the Safety Data Exchange Agreement. To the extent that there is any inconsistency between the terms of this Agreement and the SDEA, the terms of
this Agreement shall control, unless the SDEA expressly refers to the TSA in relation to such inconsistency, in which case the terms of the TSA shall control; and 

  
 4 

 4.1.8 Product Recalls. Only to the extent required by applicable Law, maintain complete
and accurate records for any periods of recall, field alert, product withdrawal or field correction of any Product. 
 4.2 The Parties
understand and agree that Distributor’s performance of services under this Agreement should not, in the ordinary course of business, require Distributor to incur material out of pocket costs. Distributor may only take actions that incur such
costs related to the provision of services under this Agreement if required by Law and only with the prior authorization of Aptevo, which authorization shall not be unreasonably withheld. For such actions, Aptevo shall reimburse Distributor within
forty-five (45) days of receipt of an invoice from Distributor regarding such costs. 
 4.3 As a condition precedent to
Distributor’s obligations under this Agreement and as a condition to each of Distributor’s representations or warranties under this Agreement, both the MSA and the Quality Agreement attached thereto as Schedule C (the
“QA”) must be in full force and effect between Emergent and Aptevo. If, at any point during the Term, either the MSA or the QA is terminated, Distributor may, in its sole discretion, either (i) indefinitely suspend any
obligation to discharge any of its responsibilities or otherwise perform under this Agreement or (ii) terminate this Agreement in accordance with Section 10.3.3. 

ARTICLE V 
 APTEVO’S
OBLIGATIONS 
 Aptevo shall discharge the following obligations at its own expense during the Term: 

5.1 Safety and Packaging. Ensure that the Product complies with local Laws as to safety, packaging and marketing and that all packaging
and delivery complies with the requirements of the Regulatory Authority of the Territory; 
 5.2 Compliance with Laws. Comply with
all Laws of the Territory that apply to Aptevo with respect to this Agreement or the transactions and activities contemplated by this Agreement; 

5.3 Regulatory Point of Contact. Subject to Section 4.1.3, serve as the primary point of contact and liaison with the applicable
Regulatory Authority with respect to all communications with such Regulatory Authority pertaining to the Products in the Territory. Aptevo shall promptly notify Distributor upon being contacted by a Regulatory Authority or any other competent
Governmental Authority within the Territory for any material regulatory purpose pertaining to this Agreement or the Products; 
 5.4
Regulatory Approval Notices. Notify Distributor immediately in the event that any Regulatory Approval for a Product is revoked for any reason in the Territory; 

5.5 Inquiry Forwarding. Keep Distributor informed of any inquiries related to any of the Products from entities within the Territory by
promptly forwarding such inquires to Distributor pursuant to Section 13.2; 

  
 5 

 5.6 Regulatory Record Keeping and Information. Maintain Product regulatory records
according to Aptevo’s standard operating procedures and in accordance with local Laws, such as submissions, regulatory agency correspondence and telephone contact reports. Distributor shall provide Aptevo with information and documents (in
English) that are in Distributor’s possession relating to each Product as are required by the applicable Regulatory Authority; 
 5.7
Material Information. Notify Distributor from time to time of any event with respect to the Product reported to Aptevo whether within or outside the Territory which Aptevo reasonably deems to be material to the distribution of the Product or
which either Party is legally required to disclose; 
 5.8 Product Improvements or Changes. Advise Distributor of all changes to the
Canadian labeling or package insert for each Product; 
 5.9 Pharmacovigilance Compliance. Until one year after the expiration date
of the last Product distributed in commerce produced under the MSA, comply with the terms and conditions of the Safety Data Exchange Agreement. To the extent that there is any inconsistency between the terms of this Agreement and the SDEA, the terms
of this Agreement shall control, unless the SDEA expressly refers to the TSA in relation to such inconsistency, in which case the terms of the TSA shall control; and 

5.10 Product Recalls. In the event of any recall, field alert, product withdrawal or field correction with respect to any of the
Products, whether initiated by Aptevo, required by a Governmental Authority or for any other reason, Aptevo shall manage such recall, field alert, product withdrawal or field correction and shall bear all reasonable costs and expenses of services
requested by Aptevo or required by any Governmental Authority relating to such recall, field alert, product withdrawal or field correction, including, without limitation, expenses or obligations to Third Parties, the cost of notifying customers and
costs associated with the shipment or recalled Products. 
 ARTICLE VI 

CONFIDENTIALITY 
 6.1
Confidentiality Obligations under the SDA. Any Confidential Information exchanged under this Agreement shall be treated as Confidential Information under the SDA, subject to the exceptions therein. Sections 7.7 and 7.8 of the SDA are
incorporated herein by reference, mutatis mutandis. 
 ARTICLE VII 

REPRESENTATIONS & WARRANTIES 

7.1 Warranties by both Parties. Each Party represents and warrants that: 

7.1.1 it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, to conduct its
business as currently conducted and to enter into this Agreement, and to consummate the transactions contemplated by this Agreement; 

  
 6 

 7.1.2 neither the execution, delivery nor performance of this Agreement by such Party violates or
conflicts with, or will violate or conflict with, any provision of such Party’s organizational or governing documents or instruments, nor are there any inconsistencies, to the best of such Party’s knowledge, between the terms of this
Agreement and any of such Party’s obligations to third parties or under applicable Law, which bind or encumber it or its property; 

7.1.3 the execution, delivery and performance of this Agreement has been duly authorized by such Party’s appropriate authorizing
authority or other applicable governing body and by any other necessary corporate or other legal actions of such Party, and this Agreement constitutes the valid and binding obligation of such Party, enforceable in accordance with its terms, except
as such enforceability may be limited by general principles of equity or bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally; and 

7.1.4 there are no actions, suits, claims or proceedings (pending or threatened) against, by, or affecting such Party in any court or before
any arbitrator or governmental agency or authority that may have a material adverse effect on such Party’s assets, its financial condition, the operation of its business or its ability to perform its obligations under this Agreement. 

7.2 Additional Warranties by Distributor. Distributor represents and warrants as follows: 

7.2.1 it possesses the necessary capabilities, facilities, personnel and expertise to enable it to perform its obligations and conduct its
activities pursuant to the terms of this Agreement; and 
 7.2.2 it has all governmental licenses, permits and approvals required by
Applicable Law to market, promote, distribute, offer for sale and sell the Products in the Territory and to conduct all of its obligations required under this Agreement. 

7.3 Additional Warranties by Aptevo. Aptevo represents and warrants as follows: 

7.3.1 the Products have received or are exempt from marketing clearances, licenses, approvals or authorizations required by Applicable Law and
therefore may be legally marketed and distributed in the Territory under such marketing clearances, licenses, approvals or authorizations or under a legally recognized exemption from the same; 

7.3.2 it shall comply with all Applicable Laws in the Territory that apply to the promotion of and sale of the Products; 

7.3.3 the Products’ labeling and promotional materials are accurate, complete, and in compliance with Applicable Law 

7.3.4 the distribution of the Products in the Territory does not and will not infringe any patent or proprietary rights of third parties; and

  
 7 

 7.3.5 there is no action or proceeding by any Governmental Authority threatened against Aptevo
relating to safety or efficacy of any of the Products, other than periodic discourse with Governmental Authorities as part of the normal course of business. 

7.4 Disclaimer of Warranties. EXCEPT FOR THE WARRANTIES SET FORTH IN SECTIONS 7.1 OR 7.2, OR AS EXPRESSLY SET FORTH IN
THE SDA OR ANY ANCILLARY AGREEMENT, DISTRIBUTOR HEREBY DISCLAIMS ALL CONDITIONS, WARRANTIES AND STATEMENTS IN RESPECT OF THE MATERIALS, THE PRODUCTS AND SERVICES PROVIDED HEREUNDER, WHETHER EXPRESS OR IMPLIED, CUSTOM OF THE TRADE OR OTHERWISE,
INCLUDING, WITHOUT LIMITATION, ANY SUCH CONDITION, WARRANTY OR STATEMENT RELATING TO MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR A PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS. 

ARTICLE VIII 
 INDEMNIFICATION AND
LIMITATION ON LIABILITY 
 8.1 Indemnification by Distributor. Subject to the limitations set forth in Section 8.4 below,
Distributor shall indemnify, defend, and hold harmless Aptevo, its Affiliates and their respective directors, officers, employees, and agents, from and against any and all Liabilities arising out of Third-Party Claims to the extent as a result of
(a) the gross negligence or willful misconduct of Distributor, its directors, officers, employees or agents in the performance of its obligations under this Agreement, or (b) any alleged or actual infringement or misappropriation of third
party Intellectual Property rights resulting from Distributor’s use of any Distributor information, data or property in the performance of this Agreement. 

8.2 Indemnification by Aptevo. Aptevo will indemnify, defend, and hold harmless Distributor, its Affiliates and their respective
directors, officers, employees, and agents, from and against any and all Liabilities arising out Third-Party Claims to the extent as a result of (a) the promotion, distribution, sale or use of any Product by Aptevo or any third party, including
any product liability claim of a third party, (b) the recall, product withdrawal, or other field correction action of any Product any Governmental Authority or otherwise, (c) the negligence or willful misconduct of Aptevo, its directors,
officers, employees or agents in the performance of its obligations or exercise of its rights under this Agreement, (d) any breach by Aptevo of the terms of this Agreement or (e) any alleged or actual infringement or misappropriation of
third party Intellectual Property rights in the Products or any portion thereof (except to the extent such claim is subject to Distributor’s indemnification obligations under Section 8.1 above), or resulting from use of any Aptevo
information, data or property in the performance of this Agreement. 
 8.3 Conditions. Promptly after a Party (the
“Indemnified Party”) obtains knowledge of the existence or commencement of any claim or proceeding with respect to which the Indemnified Party is entitled to indemnification under Section 8.1 or 8.2, such
Indemnified Party will notify the other Party (the “Indemnifying Party”) of such claim or proceeding in writing; provided, however, that any failure to give such notice will not waive any rights of the Indemnified Party except to
the extent that the rights of the Indemnifying Party are actually prejudiced thereby. The Indemnifying Party will assume the defense and settlement of such 

  
 8 

 
claim or proceeding with counsel reasonably satisfactory to the Indemnified Party at the Indemnifying Party’s sole risk and expense; provided, however, that the Indemnified Party
(i) will reasonably cooperate with the Indemnifying Party in the defense and settlement of such claim or proceeding, and (ii) may not settle any such claim or proceeding without the Indemnifying Party’s written consent. The
Indemnifying Party may not settle any such claim or proceeding without the Indemnified Party’s written consent, unless such settlement (x) includes a release of all covered claims or proceedings pending against the Indemnified Party;
(y) contains no admission of liability or wrongdoing by the Indemnified Party; and (z) imposes no obligations upon the Indemnified Party. 

8.4 Limitation on Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, THE SDA, THE TSA OR ANY OTHER ANCILLARY
AGREEMENT: 
 8.4.1 TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY
PARTY CLAIMING THROUGH OR UNDER THE OTHER PARTY FOR ANY LOST PROFITS OR REVENUES, OR FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES HOWEVER CAUSED, WHETHER IN AN ACTION IN CONTRACT, TORT (INCLUDING STRICT LIABILITY), BASED
ON A WARRANTY, OR OTHERWISE, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; 

8.4.2 DISTRIBUTOR’S LIABILITY FOR ALL CLAIMS ARISING UNDER THIS AGREEMENT SHALL NOT EXCEED THE AMOUNT PAID BY APTEVO TO DISTRIBUTOR UNDER
THIS AGREEMENT DURING THE ONE YEAR PRECEDING THE EVENT THAT GAVE RISE TO SUCH CLAIM. 
 8.5 Interaction with the SDA and other Ancillary
Agreements. Notwithstanding anything to the contrary in the SDA, in no event may any claim, including any Dispute, under or with respect to the subject matter of this Agreement be the basis of an indemnification claim under Article IV of the SDA
or under any other Ancillary Agreement. 
 ARTICLE IX 

INSURANCE 
 9.1 Distributor
Insurance. Distributor will at its own cost maintain throughout the Term of this Agreement and for a period of not less than three (3) years following its termination or expiration, liability insurance covering the obligations undertaken by
Distributor in this Agreement. 
 9.1.1 Such insurance maintained by Distributor shall, at a minimum, include coverage of the following
types and amounts: Commercial General Liability Insurance including contractual liability in an amount not less than $1,000,000 per occurrence and $2,000,000 general aggregate; Umbrella Insurance in an amount not less than $3,000,000 per occurrence
and $3,000,000 general aggregate; and Products/Completed Operations Insurance in an amount not less than $5,000,000 per occurrence and $5,000,000 general aggregate. 

  
 9 

 9.1.2 Such insurance maintained by Distributor shall name Aptevo as an additional insured. 

9.1.3 Distributor shall provide that its insurer will endeavor to mail 30 days’ prior written notice to Distributor and Aptevo should the
policy be cancelled before the expiration date thereof. 
 9.1.4 Distributor shall, on request by Aptevo, provide Aptevo with a certificate
of insurance evidencing the insurance it is required to carry under this Section 9.1. 
 9.2 Aptevo Insurance. Aptevo
will at its own cost maintain throughout the Term of this Agreement and for a period of not less than three (3) years following its termination or expiration, liability insurance covering the obligations undertaken by Aptevo in this Agreement.

 9.2.1 Such insurance maintained by Aptevo shall, at a minimum, insure the Products through a commercial policy for general and products
liability, serve as primary coverage for Distributor and Aptevo and include coverage of the following types and amounts: Commercial General Liability Insurance including contractual liability in an amount not less than $1,000,000 per occurrence and
$2,000,000 general aggregate; Umbrella Insurance in an amount not less than $3,000,000 per occurrence and $3,000,000 general aggregate; and Products/Completed Operations Insurance in an amount not less than $5,000,000 per occurrence and $5,000,000
general aggregate. 
 9.2.2 Such insurance maintained by Aptevo shall name Distributor as an additional insured. 

9.2.3 Aptevo shall provide that its insurer will endeavor to mail 30 days’ prior written notice to Aptevo and Distributor should the
policy be cancelled before the expiration date thereof. 
 9.2.4 Aptevo shall, on request by Distributor, provide Distributor with a
certificate of insurance evidencing the insurance it is required to carry under this Section 9.2. 
 ARTICLE X 

TERMINATION 
 10.1 By Either
Party. Either Party shall be entitled to terminate this Agreement by written notice to the other, having immediate effect, if: 
 10.1.1
Default. The other Party is in default in any material respect in the performance of any of its obligations under this Agreement or otherwise commits any material breach of this Agreement, and such default continues after thirty
(30) days written notice from the non-defaulting Party to the defaulting Party stating the particulars and attaching the documentary evidence of such default; or 

10.1.2 Insolvency/Bankruptcy Event. In the event of an Insolvency/Bankruptcy Event with respect to the other Party. 

  
 10 

 10.2 By Aptevo. In addition to the foregoing, Aptevo shall have the following rights to
terminate this Agreement, either in its entirety or as it relates to one or more Products, by written notice having immediate effect: 

10.2.1 Convenience. Aptevo may terminate the Agreement, in whole or in part with respect to certain Products, for convenience upon
ninety (90) day’s prior written notice to Distributor; or 
 10.2.2 Regulatory Approvals. Aptevo may terminate the
Agreement as it relates to one or more Products in the event that the Regulatory Approval for such Product(s) in the Territory is revoked by the applicable Regulatory Authority. 

10.3 By Emergent. In addition to the foregoing, Emergent shall have the following rights to terminate this Agreement, either in its
entirety or as it relates to one or more Products, by written notice having immediate effect: 
 10.3.1 Default. Emergent may
terminate the Agreement if Aptevo fails to make a payment of money, when due under this Agreement, and such default continues after thirty (30) days written notice from Emergent to Aptevo stating the particulars of such default; or 

10.3.2 Loss of Regulatory Approval. Emergent may terminate the Agreement as it relates to one or more Products in the event that the
Regulatory Approval for such Product(s) in the Territory is revoked by the applicable Regulatory Authority or in the event that such Product(s) or Aptevo generally is otherwise found to be non-compliant by the applicable Governmental Authority. 

10.3.3 Change of Distributor. Emergent may terminate this Agreement immediately upon (i) the termination of the MSA or the QA,
(ii) the assignment of the MSA or the QA by Aptevo to any third party, unless Aptevo also assigns this Agreement contemporaneously to such third party, (iii) Aptevo or Emergent ceasing to be a party to the MSA or the QA, or
(iv) Aptevo’s receipt of written notice from Emergent that Emergent no longer believes in good faith that it can perform its obligations as Distributor under the MSA or the QA. 

ARTICLE XI 
 CONSEQUENCES OF
TERMINATION 
 Upon the termination or expiration of this Agreement in whole or with respect to a given Product: 

11.1 Return of Materials. Distributor shall return to Aptevo all of Aptevo’s confidential documents (including any regulatory
submissions and files and all supporting information) in Distributor’s possession that are required by a Regulatory Authority in the Territory to maintain Regulatory Approval in the Territory for the applicable terminated Product(s); and 

11.2 No Further Representations. Distributor shall cease to make any representations to the public that it is an authorized distributor
of the applicable terminated Product(s); 

  
 11 

 11.3 Rights Terminated. All other rights granted by Aptevo to Emergent under this
Agreement with respect to the terminated Product(s) shall immediately terminate with the expiration or earlier termination of this Agreement; and 

11.4 Outstanding Payments. Aptevo shall make, honor and pay to Emergent, within thirty (30) days from termination or expiration of
the Agreement, any payments due to Emergent for services provided under this Agreement with respect to the terminated Product(s). 
 11.5
Survival of Provisions. Notwithstanding the termination of this Agreement, the following provisions shall survive: Article I (to the extent necessary to interpret the surviving provisions of this Agreement), Article VI, Section 7.4,
Article VIII, Article IX, Article XI, Article XII and Article XIII. 
 ARTICLE XII 

DISPUTE RESOLUTION 
 12.1
Resolution Process. Notwithstanding anything to the contrary in the SDA, any Dispute (as defined below) shall be resolved exclusively in accordance with the following provisions of this ARTICLE XII: 

12.1.1 Any controversy or claim arising after the Effective Time and arising out of or relating to this Agreement, or the breach hereof (a
“Dispute”), shall be resolved: (a) first, by negotiation between representatives appointed by each Party with the possibility of mediation as provided in Section 12.1.2; and (b) then, if negotiation and
mediation fail, by binding arbitration as provided in Section 12.2. Each Party agrees on behalf of itself and each of its Affiliates that the procedures set forth in this ARTICLE XII shall be the exclusive means for resolution of any
Dispute. The initiation of mediation or arbitration hereunder will toll the applicable statute of limitations for the duration of any such proceedings. 

12.1.2 Negotiation and Mediation. If either party serves written notice of a Dispute upon the other party (a “Dispute
Notice”), the parties will first attempt to resolve such Dispute by direct discussions and negotiation (including as set forth in Section 12.1 above). If the parties to the Dispute agree, the parties may also attempt to resolve
the Dispute by a mediation administered by the International Institute for Conflict Prevention & Resolution (“CPR”) under its Mediation Procedure. 

12.2 Arbitration. 
 12.2.1
If a Dispute is not resolved within 45 days (or later if mutually agreed by the Parties) after the service of a Dispute Notice, either Party shall have the right to commence arbitration. The arbitration shall be administered by the CPR pursuant to
its Arbitration Rules and Procedures. References herein to any arbitration rules or procedures mean such rules or procedures as amended from time to time, including any successor rules or procedures, and references herein to the CPR include any
successor thereto. The arbitration shall be before three (3) arbitrators. Each Party shall designate one arbitrator in accordance with the “screened” appointment procedure provided in Rule 5.4 of the CPR Rules. The two Party-appointed
arbitrators will select the third, who will serve as the panel’s chair or president. This arbitration provision, and the arbitration itself, shall be governed by the Laws of the State of Delaware and the Federal Arbitration Act, 9 U.S.C.
§§ 1-16. 

  
 12 

 12.2.2 Consistent with the expedited nature of arbitration, each Party will, upon the written
request of the other Party, promptly provide the other with copies of documents on which the producing Party may rely in support of or in opposition to any claim or defense. At the request of a Party, the arbitrators shall have the discretion to
order examination by deposition of witnesses to the extent the arbitrator deems such additional discovery relevant and appropriate. Depositions shall be limited to a maximum of five per Party and shall be held within 45 days of the grant of a
request. Additional depositions may be scheduled only with the permission of the arbitrators, and for good cause shown. Each deposition shall be limited to a maximum of one day’s duration. All objections are reserved for the arbitration hearing
except for objections based on privilege and proprietary or confidential information. The Parties shall not utilize any other discovery mechanisms, including international processes and U.S. federal statutes, to obtain additional evidence for use in
the arbitration. Any dispute regarding discovery, or the relevance or scope thereof, shall be determined by the arbitrators, which determination shall be conclusive. All discovery shall be completed within one hundred twenty (120) days
following the appointment of the arbitrators. All costs and fees relating to the retrieval, review and production of electronic discovery shall be paid by the Party requesting such discovery. 

12.2.3 Subject to ARTICLE VI, the panel of arbitrators shall have no right, power or authority, under the CPR Rules for Non-Administered
Arbitration or otherwise, to (i) award non-monetary or equitable relief of any sort; (ii) relieve the Parties from their agreement hereunder to arbitrate or otherwise to amend or disregard any provision of this Agreement; (iii) limit,
expand, alter, amend, modify, revoke or suspend any condition or provision of this Agreement; or (iv) adjudicate any matters pertaining to the SDA or any Ancillary Agreement other than this Agreement. 

12.2.4 Absent fraud or manifest error, any arbitral award issued hereunder shall be final, binding and the sole and exclusive remedy to the
Parties. Either Party may seek to confirm and enforce any final award entered in arbitration, in any court of competent jurisdiction. 

12.2.5 Except as may be required by Law or any applicable rules and regulations of any stock exchange, neither a Party nor an arbitrator may
disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties. 
 12.3
Interim Relief. At any time during the resolution of a dispute between the Parties, either Party has the right to apply to any court of competent jurisdiction for interim relief, including pre-arbitration attachments or injunctions, necessary
to preserve the Parties’ rights or to maintain the Parties’ relative positions until such time as the arbitration award is rendered or the dispute is otherwise resolved. 

12.4 Expenses. Each Party shall bear its own costs, expenses and attorneys’ fees in pursuit and resolution of any Dispute;
provided, however, that, in the event of any arbitration with respect to any dispute pursuant to Section 12.2 in which the arbitrator issues an arbitral award in an amount that is within ten percent (10%) of the amount of the most
recent bona fide 

  
 13 

 
written settlement offer submitted by a Party and rejected by a Party in connection with such dispute, then the Party that rejected such settlement offer shall bear both Parties’ costs,
expenses and attorneys’ fees incurred in connection with such arbitration (including the fees and expenses of any arbitrator). 

ARTICLE XIII 
 MISCELLANEOUS 

13.1 Provisions from the SDA. The Parties agree and acknowledge that this Agreement is an Ancillary Agreement and, therefore, that
certain provisions of the SDA apply hereto, provided, however, that if there is any conflict between the terms of this Agreement and the terms of the SDA, the terms of this Agreement apply with respect to the subject matter hereof. Sections 11.1
(Counterparts; Entire Agreement; Corporate Power), 11.2 (Governing Law), 11.6 (Severability), 11.7 (Force Majeure), 11.10 (Headings), 11.11 (Survival of Covenants), 11.12 (Waivers of Default), 11.14 (Amendments), 11.15 (Interpretation) and 11.16 (No
Set Off) of the SDA are incorporated herein by reference, mutatis mutandis. 
 13.2 Notice. All notices, requests, claims,
demands or other communications under this Agreement and, to the extent applicable and unless otherwise provided therein, under each of the Ancillary Agreements shall be in writing and shall be given or made (and shall be deemed to have been duly
given or made upon receipt) by delivery in person, by overnight courier service, by facsimile or electronic transmission with receipt confirmed (followed by delivery of an original via overnight courier service) or by registered or certified mail
(postage prepaid, return receipt requested) to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance with this Section 13.2): 

If to Emergent, at: 
 [●] 

with a copy to: 
 [●] 

and a copy to: 
 [●] 

if to Aptevo, at: 
 [●] 

with a copy to: 
 [●] 

Any Party may, by notice to the other Party, change the address and contact person to which any such notices are to be given. 

  
 14 

 13.3 Assignability. 

13.3.1 This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.
Except as otherwise provided for in this Agreement, this Agreement shall not be assignable by either Party, in whole or in part, without the express written consent of the other Party, which shall not be unreasonably withheld, and any attempt to
assign any rights or obligations arising under this Agreement without such consent shall be void. Notwithstanding the foregoing, no such consent shall be required for the assignment of a Party’s rights and obligations under this Agreement
(i) in connection with the merger of such Party, or the sale, transfer or other divestiture of all or substantially all of an entire product line, Affiliate, division or other business unit of such Party, or (ii) to any Affiliate of such
Party. 
 13.3.2 In connection with any assignment or delegation of this Agreement or the rights and obligations herein, the assigning or
transferring Party shall provide a guarantee to the non-assigning Party for any liability or obligation assigned or delegated pursuant to this Section 13.3. 

13.3.3 The assigning Party shall remain bound by all obligations with respect to Confidential Information under this Agreement. The
non-assigning Party may disclose the assigning Party’s Confidential Information to the assignee as necessary for the non-assigning Party’s performance of its obligations and exercise of its rights under this Agreement. 

13.4 No Agency. Nothing in this Agreement shall be deemed in any way or for any purpose to constitute any Party an agent of an
unaffiliated party in the conduct of such other party’s business. 
 13.5 Quality Agreement. The QA shall, together with this
Agreement, apply to the provision of any service contemplated under this Agreement solely to the extent such service relates to quality assurance matters and is within the subject matter of the QA. In the event of any conflict or inconsistency
between the QA and this Agreement solely with respect to quality assurance matters, the QA shall control. In the event of any other conflict or inconsistency (including, for the avoidance of doubt, with respect to the respective remedies of the
parties with respect to any service contemplated under this Agreement), this Agreement shall control. 
 [Signature Page Follows] 

  
 15 

 IN WITNESS WHEREOF the Parties have duly executed this agreement as of the date first
above written. 
  

			
	EMERGENT BIOSOLUTIONS INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	APTEVO THERAPEUTICS INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

			
	LIST OF SCHEDULES:
		
	Schedule A.	  	Product Schedule
		
	Schedule B.	  	Distributor Fee Schedule

 Schedule A 

Product Schedule 
  

			
	 Product
	  	 Description

 Schedule B 

Distributor Fee Schedule

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]